Introduction. Stem cell transplantation (SCT) from non HLAidentical family donors (NIFD) is asociated with an increased risk of graft failure as well as of GVHD. The use of T cell depleted (TCD) grafts reduces the risk and severity of GVHD but increases graft failure and disease relapse. Objective: To evaluate the utility of chimaerism and minimal residual disease (MRD) quantification for the prediction/early detection of such processes. Patients and methods: We present 6 TCD-SCT using PB grafts from 6 NIFD, performed to 5 patients (Table 1) . Chimaerism quantification was done by FISH and STR-PCR. MRD was analyzed by FISH in those cases with identified chromosome markers i(7q) in UPN 93 and tetrasomy X in UPN 181) as well as by RT-PCR/BCR-ABL in UPN 46. Analyses were performed on BM and PB samples, as well as on leukocyte lineages: T cells (CD3+, CD4+, CD8+), B cells (CD19+) and mieloid cells (CD15+). Results: Table 1 shows the evolution of chimaerism and MRD in the clinical context of each patient.
Conclusions: Chimaerism and MRD quantification has shown to be of great utility for the follow up of high risk transplants such as those performed f rom NIFD. It favoured the prediction/early detection of disease relapse and graft rejection episodes and drove the use of DLI in their treatment. Moreover, it allowed the follow up of the efficacy of the immunotherapy with DLI. The observation of mixed chimaerism was asociated with complications with the graft or with disease relapse. DLI was successfully used to obtain complete chimaeras in patients in relapse (through their graft vs leukemia effect) and in patients with problems with their grafts, exploiting the graft vs recipient haemopoiesis effect. @SCT from NIFD (sister) after exitus of the first NIFD (mother). *Absence of patient cells; mixture of cells from both NIFD.
Follow-up of SCT by FISH on unmanipulated bone marrow and blood smears M. Walther , M. Fuehrer, U. Rampf, C. Bender-Goetze, J.-U. Walther (Munich, D) Objective: Advanced strategies of SCT necessitate a sensitive and practical method of identifying persisting host and/or clone specific cells during follow-up. We tested molecular interphase cytogenetics with FISH on routine PB and BM smears for sensitivity, clinical reliability and practicability. Patients: 43 children after SCT with sex mismatch (37) and/or clone specific markers. Diagnoses: AL (22), MDS (8), CML (4), LCAL (1) and SAA (8). Methods: FISH using commercial probes (CEP X, Y, 7, 8 ; LSI bcr/abl and MLL) on fresh or stored unmanipulated smears of PB or BM. Evaluation: Cut-off levels for presence of clonal markers and/or host sex were established on control probands without hematological disease (mean + 3 SD). For definition of complete chimerism an arbitrary cut-off level was set at 1% to allow for contamination by non-hematological host cells. Results: Patients were classified as retrospective (group I: grafted before 4/97 and studied 2-14 years (mean 6y) after SCT) or prospective (group II: analysed since 1997 at regular intervals). Group I : Among 23 long term survivors after sex mismatched SCT 2 showed significant numbers of host cells at 7 resp.13 y after SCT, one of them in increasing proportions without evidence of leukemia. In one pt with relapse after 1. SCT host and clone specific cells (MLL) were identified before and after 2.SCT. Group II: In 2/17 cases with morphologic remission but short follow-up (2 mo) host and/or clone specific markers (bcr/abl) were found, 1 of them proved to be negative after cessation of immunosuppression. The other pt died from severe GvHD. 3 pts with BM relapse showed host and clone specific markers (monosomy 7 , bcr/abl, MLL resp.), in 2 of them immunotherapy was monitored successfully by FISH, 1 died early after SCT. In addition, FISH allowed identification of host cells in non-hematological material (CSF, pericardial effusion) in 2 cases. FISH in BM was slightly more sensitive for host cells than in PB. Conclusion: We demonstrated the usefulness of FISH on smears from uncultivated BM and blood for follow-up and monitoring therapeutic interventions after SCT.
A single nucleotide polymorphism in the TNF type II receptor (TNFRII) gene, at codon 196, results in the substitution of arginine (R allele) for methionine (M allele) . The R allele is reported to associate with an increased susceptibility to autoimmune disease and donor R allele carriage correlates with acute Graft-Versus-Host Disease (GVHD) severity after MUD BMT. To investigate the functional impact of this polymorphism, 81 volunteer blood donors were genotyped by PCR and SSCP analysis. Plasma soluble TNFRII (sTNFRII) levels were measured by ELISA in this cohort. Mean plasma sTNFRII levels (+/-SEM) were 1225+/-26 and 1063+/-65 for individuals carrying at least 1 M allele (M+) and RR homozygotes respectively (p=0.02). Given this finding we examined the impact of this polymorphism on acute and chronic GVHD incidence/severity after non-T celldepleted sibling BMT. TNFRII 196 M/R genotype was determined, as described, amongst 106 transplant recipients, 106 donors and 131 control subjects. R allele frequency amongst recipients, donors and controls was 0.28. In univariate analysis there was a trend towards increased acute GVHD incidence [odds ratio (OR) 2.9] amongst R+ recipients (p=0.1). In multivariate analysis by logistic regression, correcting for established clinical and genetic GVHD risk factors, the impact of recipient TNFRII R+ status was reduced (p=0.13).
In univariate analysis, donor RR homozygosity associated with a trend to increased cGVHD incidence (OR 4.6; p=0.1) and an increased risk of extensive cGVHD (OR 8.5; p=0.01) . In multivariate analysis donor RR homozygosity associated with an increased risk of extensive cGVHD (relative risk 11.3; p=0.02) but not cGVHD incidence per se. Since sTNFRIIs can act as TNF antagonists, the association between donor RR homozygosity and cGVHD may reflect reduced circulating sTNFRII. The role for pharmacological interventions, particularly the use of recombinant sTNFRII (Etanercept) requires further investigation, but may be influenced by genotype.
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Efficacy of photopheresis in the management of steroid refractory chronic graft-versus-host disease P. Taylor (Rotherham, UK) Photopheresis (ECP) has been used successfully in the management of a variety of T cell mediated diseases including chronic graft versus host disease (cGvHD). A lymphocyte rich buffy coat is photoirradiated after addition of a photosensitiser and returned to the patient. 30 patients with steroid refractory cGvHD (extensive) following allogeneic bone marrow or peripheral blood stem cell transplant were treated with ECP over a period of 3-18 months (mean 9.5). The underlying diagnoses were AML 8, CML 7, ALL 4, Lymphoma 4, Myeloma 3, myelofibrosis 2, CLL 1, SCID 1. The interval from transplant to cGvHD was 3-43 mths (mean 9.7) and from cGvHD to ECP 5-60 mths (mean 16.7). 26 patients had mucocutaneous disease, 3 respiratory disease and 1 primary hepatic cGvHD. Presentation therapy included, prednisolone 26, cyclosporin 24, myocphenolate 5, thalidomide 5, azathiaprine 5. Assessments were made of skin score (subjective assessment of extent and thickness of skin involvement), weekly prednisolone dosage and liver function tests. All patients tolerated ECP, central catheters were required in 2 patients due to limited peripheral venous access. There was a significant and progressive decrease in skin score from months 3 to 12 (mean 103 to 35; p=<0.01), only 1 patient showed evidence of cutaneous progression, 3 showed no change at three months. Concurrent steroid therapy was significantly reduced by month 3 (mean weekly dose 150mg to 92mg; p=0.01), 5 patients remained on their initial dose, 1 patient required an increased dose. Respiratory function improved by month 6, (PEFR 1.36 to 1.63 L/min; P=0.04). Liver enzymes were abnormal in 24/30 patients at initiation of ECP. Whilst there was a reduction in the mean enzyme (gamma GT) level at 3 months, this did not reach statistical significance (mean 228IU/l to 180IU/L; p=0.07). Of those with abnormal initial results 5 became worse, 1 no change. Of those that were initially normal non showed evidence of deterioration in the first 12 months. Six patients died during the period of follow up, 3 in the first 3 months (infection, progressive liver GvH, cardiac arrhythmia), and subsequently at 6,12 and 24 mths respectively after commencing ECP all with respiratory infections. ECP is a safe and effective treatment for the management of the cutaneous manifestations of steroid refractory cGvHD.
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patients is very low. Pulse Cyclophosphamide (CP) is the established treatment for some autoimmune disorders. Because of several similarities between GvHD and autoimmune diseases, we decided to try pulse CP as a salvage treatment in severe GvHD patients non-responding to corticosteroids. Methods: Administration of pulse CP as an i.v. infusion at the dose of 15-20 mg/kg. If needed, further pulses were planned at the time intervals 4 -6 weeks. Other immunosuppression (corticosteroids, cyclosporin A, mycophenolate mofetil) was maintained or gradually tappered. Results: Five patients were treated so far. The first patient (CML, 30 years) developed steroid-refractory autoimmune hemolytic anemia during the chronic GvHD. She responded to a one course of pulse CP. The mucosal involvement was not influenced, however. The second patient (MDS, 31 years) developed severe acute GvHD with liver and oral involvement. He responded to one pulse of CP and now, only limited cGvHD of the liver is present. The third patient (CML, 27 years) developed predominantly very severe hepatic involvement, with significant gradual improvement after one course of pulse CP. The fourth patient (AML, 43 years) developed severe GvHD of the liver, skin, and oral cavity after DLI administration. He responded very well, developing mild chronic GvHD of the liver only. The last patient (CML, 20 year, MUD BMT) developed predominant intestinal involvement during the acute GvHD. He did not responded to the pulse CP. Evident signs of clinical and laboratory improvement occurred in the time interval of 1 week upon the administration of pulse CP. Surprisingly, administration of the pulse CP was accompanied only by mild and self-limiting neutropenia. No further or serious complications were seen. Conclusion: Pulse CP seems to be cheep, effective and nontoxic treatment of steroid-refractory GvHD.
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No significant correlation between mismatched minor histocompatibility antigen HA-1 and the development of acute graft versus host disease after HLA identical sibling bone marrow transplantation in Sardinian patients M.G. Orofino, M. Badiali, M.A. Sanna, C. Addari, F. Rizzo, A. Piroddi, F. Argiolu (Cagliari, I) Recipient mismatching for minor histocompatibility antigen HA-1 has been associated with acute graft versus host disease (aGvHD), after allogeneic bone marrow transplantation. The HA-1H peptide that generates this response, is known to be presented by HLA*0201. In order to investigate the aGVHD impact in 101 Sardinian recipients who had received a marrow stem cell transplantation from an HLA identical sibling, we retrospectively examined HA-1 typing with PCR SSP (sequence specific primers) in 61 HLA-A2 positive bone marrow transplantation recipients.Thirty five (34.6%) of 101 patients developed grade II-IV aGVHD. GVHD prophylaxis consisted of either only cyclosporine (80%) or cyclosporine and methotrexate (20%). The median age of recipients was 13.3 (range 18 months -32 years). Beta-Thalassemia was the most frequent disease; others included LLA, AML, Histiocytosis, Fanconi Anemia, Hodgking disease, Primary Immunodeficiency, Severe Aplastic Anemia. Material and Methods: HA-1 genotyping testing was performed using allele -specific primers to amplify HA-1H and HA-1R alleles. The presence of HLA A*0201 was performed by the sequencing of the amplified HLA-A2 gene. Results: Recipient HA-1 disparity (donor HA-1 RR/patientHA1-HH or HR) was detected in 13 of the 61 donor/recipient pairs (21.3%). HLA-A*0201 was present in 10 of the 13 donors. The others 3 had HLA-A*0205 and were escluded from further analysis. Four of the 10 patients (40%) with HA-1 mismatched developed grade II-IV aGVHD, compared with 6 of the 28 patients HLA*0201 HA-1 matched (21%); Odds ratio 2.44, 95% CI 0.5-11.6, P 0.25. This univariate analyse did not show significant difference in the incidence of aGVHD between incompatible and compatible patients. This non significant association could be related to the low frequency of HA-1 disparity that makes it very difficult to demostrate significant association with aGVHD after allogeneic bone marrow transplantation statistically. A very large multicenter study would be needed in order to have an adequate statistical power to detect association of HA-1 mismatched and graft versus host disease.
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Graft-versus-host disease and graft-versus-tumor effect following allogeneic HLA-identical sibling transplantation with anti-T-lymphocyte globulin-based reduced-intensity preparative regimen M. Mohty, J.O. Bay, C. Faucher, B. Choufi, K. Bilger, N. Vey, A.M. Stoppa, D. Coso, P. Viens, C. Chabannon, D. Blaise (Marseille, Clermont-Ferrand, F) Reduced intensity conditioning regimens (RIC) are increasingly used in the allogeneic stem cell transplant setting. RIC has been shown to allow engraftment with minimal early transplant-related mortality (TRM). However, in the context of RIC, predictive factors for acute and chronic graft-versus-host disease (GVHD) (aGVHD, cGVHD) and their impact on outcome remain unknown. In this report, we analyzed the outcome of 101 consecutive high risk patients who received an HLA-identical sibling allogeneic graft after RIC i ncluding fludarabine, busulfan and anti-T lymphocyte globulin (ATG). Median age of recipients was 50 years. 25 patients were treated for myeloid malignancies, whereas 45 patients had lymphoid malignancies. 31 patient were treated for refractory metastatic non-hematological malignancies. 47 patients received a bone marrow graft, whereas 54 received PBSC. As part of the protocol, the total ATG dose administered during conditioning was progressively decreased from 10 mg/kg to 2.5 mg/Kg with the aim of modulating GVHD, and thereby potentially the putative graft-versus-tumor (GVT) effect. Twenty five patients received the higher total ATG dose of 10 mg/kg, 21 patients received a total dose of 7.5 mg/kg, while the remaining 55 patients received the lower ATG dose of 2.5 mg/Kg. A sustained ANC of more than 500/µL was reached at a median of 15 days (range, 9-23 days). Platelet engraftment occurred at a median of 14 days (range, 0-99 days). The cumulative incidence of grade II-IV aGVHD was 36% (95% CI, 27%-45%) while the cumulative incidence of extensive cGVHD at 2 years was 26% (95% CI, 17%-35%). In multivariate analysis, the incidence of aGVHD was significantly associated with the ATG dose infused during conditioning (P= .001), while peripheral blood as stem cell source was the only predictive factor for the development of cGVHD (P= .0004). The 1-year cumulative incidences of disease progression or relapse in patients with (n = 69) and without (n = 31) GVHD (whatever its form or grade) were 30% (95% CI, 19%-41%) and 5 5% (95% CI, 37%-72%), respectively (P= .02), suggesting that a potent GVT effect can be achieved in high risk patients following RIC allogeneic transplantation. This GVT effect was closely associated with GVHD without an increased risk of TRM [cumulative incidence of TRM, 16% (95% CI, 9%-23%)]. Collectively, these results provide a framework for the refinement of low intensity approaches designed to enhance the GVT effect with an acceptable risk of GVHD.
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Dickinson et al. (Human Immunology, 2001 , 62: 1266 -1276 showed correlations between the gene variants of cytokines and severity of aGvHD. Objectives: Our study sought to assess the significance of two proteolysis-related gene polymorphisms as probable markers of donor chimerism, and potential risk factors of aGvHD. Methods: Promoter alleles of plasminogen activator inhibitor-1 (PAI-1-675 5G/4G variants) and interstitial collagenase (matrix metalloproteinase-1, MMP-1 -1607 1G/2G alleles) were studied in donors and recipients for 120 consecutive HSCT cases, employing original allele-specific DNA PCR techniques. Results & Discussion: The studied allele pairs were in genetic equilibrium for the patients and control group. The frequency of PAI-1 promoter variants was similar among donors and recipients.
Among 127 donor-recipient pairs, allelic polymorphism of MMP-1 and PAI-1 genes could be used for the detection of hematopoietic chimerism in 28% and 32% of cases. Single-step DNA-PCR was shown to be sensitive for gene markers assayed (detection of >0.1% recipient cells), thus allowing detection of recipient leukocyte DNA in the range of 0.1 to 10%. Meanwhile, homozygous state for the highly inducible MMP-1-1607 (2G/2G) allele was significantly reduced in patients with aGVHD as compared to GVHD-free patients, whereas presence of MMP-1 2G/2G in donor cells correlated with higher incidence of aGVHD (p=0.02). In combination, both risk factors (recipient: 1G, donor: 2G allele) were significantly associated with increased aGVHD risk (p<0.008). The 2G "hyperactive" allele known to be highly inducible may provide increased invasive capacity of cells based on higher MMP-1 production. Conclusion: DNA PCR of PAI-1 and MMP-1 promoter alleles allows to detect donor chimerism in ca. 40% of cases. The results also suggest an important role of donor/recipient discrepancy in MMP-1 gene alleles with respect to aGvHD risk. Probable involvement of MMP-1 in aGvHD may offer novel treatment strategies for this complication.
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Estrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA matched sib-allo BMT P. Middleton, J. Norden, H. Cullup, J. Cavet, G. Jackson, P. Taylor, A. Dickinson (Newcastle upon Tyne, UK) Estrogen receptors mediate the cellular response to estrogens and related compounds and promote a wide range of effects on haemopoiesis. Polymorphisms of the estrogen receptor genes have previously been associated with variation in bone mineral density, likelihood of fractures, risk of developing Alzheimer's disease, endometrial cancer and response to hormone replacement therapy. We examined the polymorphisms in both ER alpha and ER beta genes in 108 patients and their donors from a single transplant centre, receiving a bone marrow transplant from an HLAmatched sibling donor. We compared ER genotype with outcomes of occurrence of graft versus host disease (GVHD) and survival using logistic regression analysis. Polymorphism of ER alpha (presence of the PX haplotype (PvuII -XbaI RFLP) of intron 1), but not ER beta, in the patient genotype associated with occurrence of acute GVHD grades II -IV (OR 2.818, P = 0.019), as did patient age >40 years (OR 4.329 P = 0.016), patient IL-6 genotype (OR 4.129, P = 0.004) and CMV status (0.398, P = 0.051). The same ER alpha genotype showed a trend towards lower overall survival. Stratification of the study group into patients who relapsed and those that did not, showed that the ER alpha genotype was associated with early death in the non-relapse group (ie early transplant related complications). Analysis of ER genotype prior to transplant might inform on a patients likelihood of developing post-transplant complications. Variation in transplant performance due to ER genotype suggests an underlying role for estrogens in the pathophysiology of transplant related complications and suggests that estrogen related therapy may offer a new modality of post-transplant support.
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Immunomodulation by extracorporeal photochemotherapy to treat acute and chronic GVHD both in children and adults C. Perotti, G. Viarengo, S. Carbone, S. Bernuzzi, C. Del Fante, P. Bergamashi, F. Locatelli, A. Marchesi, L. Salvaneschi (Pavia, I) Acute and chronic GvHD strongly affect morbidity and mortality after stem cell transplantation. Moreover immunosuppressive therapy (IST) administered in order to control GvHD manifestations heavily engraves on post-transplant related infections and on the development of secondary neoplasia. In this scenario, a new therapeutical approach based on immunomodulation rather than a more aggressive IST is strongly desirable. Extracorporeal Photochemotherapy is a new therapeutic strategy consisting in a mononuclear cells (MNC) collection by a blood cell separator, dilution of the collected MNC with saline after 8 Methoxy Psoralen addition, irradiation with UV-A light and the reinfusion of the manipulated MNC to the patient. Our Treatment Protocol consists of 2 consecutive procedures/week for 3 weeks, then 2 consecutive procedures every 2 weeks for 3 courses, followed by 2 procedures monthly. We present our results about 56 patients (35 adults, 21 pediatrics) affected with grade II-IV chronic GvHD (Skin, mucosaes, liver and lung)and 18 pediatric patients affected with grade II-IV acute GVHD (skin, mucosaes, liver, gut). The mean patient's age was 38.5 (18-49), 12.5 (6-20), 10.7 (5-17) in adults and pediatrics with cGvHD and in pediatrics with aGvHD respectively. We performed an average of 23.9 procedures (4-46) in adults with cGvHD, while in the pediatric setting of patients with cGvHD and aGvHD the mean number of procedures was 32.6 (8-93) and 20.7 (6-73) respectively. The response rate in adult and pediatric patients with cGvHD was 85% and 75% respectively, while in pediatric patients with aGvHD the response rate was 62%. It's to underline that we were able to taper or suspend IST in the 80.5%, 66.7% and 56% of adults and children with cGvHD and children with aGvHD respectively. Extracorporeal Photochemotherapy reconfirmed its effectiveness as a second line therapy in the treatment of GvHD, demonstrating great safety and tolerability. The possibility to decrease IST improved quality of life minimizing long term drugs related side effects. Even from an economical point of view Extracorporeal Photochemotherapy demonstrated to be a costeffective therapeutical approach especially for long term survivals.
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Infliximab for treatment of steroid refractory acute and chronic graft-versus-host disease R. Trenschel, C. Trampenau, M. Ditschkowski, A. Elmaagacli, H. Ottinger, N. Steckel, H. Biersack, R. Peceny, D. Beelen (Essen, D) Stem cell transplant recipients with steroid refractory graft versus host disease (GvHD) have a poor prognosis. Nowadays, several monoclonal antibodies are available to influence the cytokine cascade activated by alloreactive cells. Infliximab a chimeric human/mouse anti TNF á antibody was given to 9 patients (median age 41 years) (AML 2, CML 4, MPS 1, ALL 1, MM 1) for severe steroid refractory GvHD. Steroid refractory GvHD was defined as no response or clinical progression to prednisolone (PDN) 2 mg/kg BW followed by an escalation to PDN 5mg/kg BW over at least 2 weeks. Myeloablative conditioning regimen was based on TBI (n=7) or on chemotherapy (n=2) followed by short course MTX and CSA as primary prophylaxis of GvHD. All patients developed severe intestinal involvement (grade III -IV) in addition to skin (n=8) and liver (n=2) disease. Patients with acute GvHD received infliximab at a dose of 10 mg/kg BW (n=2) or 5 mg/kg BW (n=1). For chronic GvHD (n=6) 5mg/kgBW was given. Treatment was repeated at least twice. In case of no response or progression of GvHD, no further application was performed. Three patients received 2 courses, four patients 3 courses and one patient 6 respectively 11 courses. Three of nine patients achieved a complete remission, 3 patients a partial remission, and 3 patients showed progression of GvHD. Median follow up starting from first infusion of infliximab is 79 days (14 -603). Only one patient is actually alive at day 603 without any sign of GvHD. The other patients died from invasive fungal infection (n=6), BOOP (n=1), or MOF (n=1). Thus, infliximab seems to be an active drug for the treatment of acute and chronic intestinal GvHD but long term survival is very poor as a result of fatal opportunistic infections.
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Clinical and genotypic risk factors for GVHD are modulated by prophylaxis: a multicenter cohort study of HLA matched sib-allo BMT P. Middleton, M. Jarvis, H. Cullup, G. Jackson, I. Hromadnikova, E. Holler, H. Kolb, A. Dickinson (Newcastle upon Tyne, UK; Prague, CZ; Regensburg, Munich, D) Clinical and genotypic risk factors associate with outcome following allo-BMT. Prophylaxis is known to affect the relevance of clinical risk factors, but its effect on genotypic factors has not yet been established. We compared genotype and clinical risk factors with GvHD and survival in a four centre study representing a full spectrum of transplant patients (n = 230). The patient population was heterogeneous for disease diagnoses, age range etc. Logistic regression analysis was used to identify any risk features (genotype for TNF alpha, IL-10, IL-6, IFNgamma, IL-1Ra, vitamin D receptor (VDR), estrogen receptor (ER)) which were still predictive of GVHD irrespective of increased or modified GvHD prophylaxis. Cox regression analysis was used to analyse survival, We found that prophylaxis regimen modified the degree to which different features associated with GvHD. With prophylaxis restricted to CsA, aGVHD was associated with CMV status, a positive GVHR test, and genotype for patient IL-1Ra, donor IL-10, ER and TNF alpha with different associations being seen depending upon how GVHD severity was dichotomised. Chronic GVHD was associated with patient age(>40), gender mismatch transplant, disease stage at transplant and patient genotype for IL-10, IL-6 and IL-1Ra. In patients where prophylaxis included additional agents including methotrexate, aGVHD associated with patient age (>40) and CMV status and with patient IL-6 genotype for all grades of aGVHD; cGVHD associated with age (>40), previous aGVHD, positive skin explant result and patient genotype for TNFalpha, IL-10, IL-6 and VDR. Prophylaxis did affect overall survival. Pre-transplant features associated with survival were age (>35) and gender mismatch and donor VDR genotype and patient ER genotype. Genotypic risk factors are as important as other known clinical features associated with GvHD risk, with both being influenced by the prophylaxis protocol. Some genotypic risk factors may be widely applicable. , namely IL-1Ra in CsA prophylaxis protocols and IL-6 in protocols using additional methotrexate.
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Interleukin-6 gene polymorphisms associate with acute graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation N. Gurses, S. Kalayoglu-Besisik, D. Sargin, B. Ferhanoglu, S. Anak, T. Soysal, Z. Baslar, S. Ongoren, H. Bilgen, G. Gedykoglu, M. Aydin, N. Abacy, A. Gul, U. Ozbek (Istanbul, TR) Graft-versus-host disease (GvHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Proinflammatory cytokines, their receptors and inhibitors including interleukin-1 (IL-1), IL-1 receptor antogonist (IL-1Ra), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor alpha (TNF-alpha) are important mediators and regulators of GvHD. Recently, it was shown that numbers of polymorphisms alter the production of these genes. We have studied the precence of functional polymorphisms in TNF-alpha (-308 G/A), IL-10 ( -1082 A/G), IL-6 ( -174 G/C), IL-1 ( -511 C/T), IL-1 Ra (intron 2) genes and assess the risk of these cytokine genotypes with respects to established risk factors for GvHD. The subjects were 175 consecutive patients and their donors who underwent allo HSCT between 1995-2002 in 3 BMT Units of Istanbul University (adult n=133, age range=18-54, mean=30.2 years; children n=42, age range=1-17, mean=10.3 years). The diagnosis were: CML, n =62; AML, n=52; ALL, n=27; others, n=34). We have found positive association between IL-6, -174 G genotype which contributes to the up-regulation of the gene and acute GvHD in all groups (P= 0.15, OR: 1.59, 95% CI: 1.37-1.86). There was no other correlations when we compare all the 5 genotypes with acute GvHD, chronic GvHD and survival. No association of either polymorphisms tested with GvHD was found in donors. We conclude that, assesment of cytokine genotype may potentially allow prediction of GvHD and could be indicative for future studies of GvHD studies.
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Extracorporeal photochemotherapy in the treatment of acute and chronic graft-versus-host disease P. Bavaro, P. Accorsi, G. Di Girolamo, M.T. Massaro, P. Olioso, G. Papalinetti, P. Di Carlo, S. Santarone, P. Striani, A. Iacone, P. Di Bartolomeo (Pescara, I) Allogeneic stem cells transplantation (SCT) is frequently complicated by GvHD, which may be refractory to immunosuppressive drugs. Extracorporeal photochemotherapy (ECP), a treatment that affect allo-targeted effector T cells and antigen-presenting DCs, has recently been proposed for the treatment of patients with either acute or chronic GvHD. From august 1999 to october 2002, 16 pts (7 M and 9 F) who had received SCT (13 BM, 3 PBSC) from related donors were treated by ECP for steroid refractory aGvHD grades II to IV or cGvHD limited or extensive. Median age was 39 (range, 13-49) yrs; 4 pts had ALL, 3 AML, 5 CML, 2 MM, 1 NHL, 1 breast cancer. Therakos-XTS ECP system was performed on outpatient basis or inpatient basis if requered. The protocol consisted of 2 consecutive days ECP every week for the 1st month, every 2 weeks for the 2nd month and once a month for at least 4 months or until resolution of GvHD. Response was graded as complete (resolution of all manifestations), partial (50% improvement in organ involvement), no change (response lower than 50% and reduction of other immunosuppressive therapy), progressive disease (development of new signs or symptoms or worsening of existing lesions). Results: at a median follow-up of 8 (range, 7-36) months, 356 ECP procedures had been completed. No severe side effects were documented. Among the 5 pts with aGvHD II-III (4 pts with skin, 1 pt with liver involvement), 2 ALL pts had received DLI for relapse prophylaxis. Three pts experienced complete resolution of aGvHD, but needed to continue ECP for progressive cGvHD, one pt died due to liver failure, one pt reached a complete S130 response after 4 cycles of ECP. Among the 14 pts with cutaneous and mucosal (11 pts) and/or visceral (13 pts) manifestations of cGvHD (limited in 5 pts, extensive in 9 pts, 2 of them after DLI), 5 pts did not ended the scheduled ECP (2 pts for life-threatening infections, 1 pt for CML relapse, 1 pt for blood hypercoagulability in the ECP system, 1 pt for refusal after 7 ECP cycles); 4 pts are in CR after a median of 14 (12-17) cycles; 5 pts achieved PR after a median of 11 (7-25) cycles. For all CR pts was possible to tapering and discontinue PDN and reduce the remaining immunosuppressive drugs. Steroid therapy was discontinued in 5 PR pts, and reduced in one PR pt. Conclusion: ECP is safe and effective in pts with either acute or chronic GvHD heavily pre-treated, the tolerance is good and the infectious complications are few.
P544 Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by use of Helinx technology
Helinx technology uses small molecules including amotosalen HCl (S-59) that targets nucleic acids. The application of Helinx technology is dose dependent. Amotosalen at 150 micro-molar and 3 J/cm² UVA used by the INTERCEPT Blood Systems has been shown to inactivate a broad spectrum of viruses, bacteria, protozoa, and leukocytes, while 9 nM amotosalen and 3 J/cm² UVA has been shown to have immunomodulatory effect on Tlymphocytes. The proliferation of donor T-cells in vivo is the principal cause of graft-versus-host disease (GVHD). This study evaluated the efficacy of Helinx technology for prevention o f GVHD. In an immunocompromised murine bone marrow transplant (BMT) model, addition of 0.5 to 3.0 x 10^6 untreated donor (B10.BR) T-cells to T-cell depleted (TCD) BM resulted in acute GVHD in transplant recipients (CBA). However, recipients receiving TCD BM with 3.0 to 30.0 x 10^6 donor T-cells treated with 150 micro molar amotosalen and 3 J/cm² UVA remained free of GVHD. This finding correlated with the inactivation of >10^5.4/mL viable T-cells in a clonal T-cell proliferation assay. Human leukocytes when treated with 9 nM amotosalen and 3 J/cm² UVA inhibited >90% proliferation of T -cells. Cytokine synthesis (IL-2 and IFN-g), cell surface antigen expression (CD25 and CD69), and cytotoxic T-cell activity were conserved. In a MHC-mismatched murine BMT model, the addition of treated T-cells to TCD BM facilitated donor engraftment and complete chimerism without causing acute or chronic GVHD, while conserving allospecific graft-versus-leukimia (GVL) activity. In an MHC-matched model using host-presensitized donor Tcells, treatment with amotosalen and UVA significantly reduced GVHD-associated mortality without adversely affecting GVL activity.
In conclusion, the dose of amotosalen is important for the various applications of Helinx technology. Treatment with 9 nM to 150 micro molar amotosalen and 3 J/cm² UVA is effective for prevention of GVHD, while 150 micro molar of amotosalen and 3 J/cm² UVA treatment is required to achieve high levels of pathogen inactivation and prevent cytokine synthesis. In addition, Helinx treatment ex-vivo offers a simple method to control the fate of naïve and primed T-cells in vivo.
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HLAs and other risk factors for acute GVHD in hematopoietic stem cell transplanted thalassemia patients from HLA identical siblings M. Mohyeddin, K. Alimoghaddam, F. Forouzia, S. Vatandoust, M. Jahani, A. Ghavamzadeh (Tehran, IR) Background: Many studies have identified some risk factors such as T cells, age and sex mismatch for aGVHD. Recent reports have suggested a probable association between certain HLA antigens and aGVHD. Patients and Methods: We investigated 171 beta thalassemia patients who received HSCT from an HLA-identical sibling between 1991-2002 in our center.Fifty four patients (30%) were thalassemia class I, 72 (40%) class II, and 52 (30%) class III. There were 95 males and 80 females with a median age of 6 years (range 2 -24years).The conditioning regimen included busulfan plus cyclophosphamide and aGVHD prophylaxis included cyclosporine and methotrexate.Patients were categorized into three groups including no aGVHD (grade 0), mild aGVHD (grade I-II), and severe aGVHD (grade III-IV). Each of the probable risk factors, including HLA antigens, age, ABO mismatch, sex mismatch, class of thalassemia, transplanted nucleated cell dose, duration of e ngraftment (ANC>500) and consumption of blood products, were examined individually for possible relationships with aGVHD according to our categorized groups. The probable associations were tested in univariate analyses using the Pearson chi-squared and t.test statistics. Results: among the 171 patients, 59 (34.2%) developed severe aGVHD (grade III-IV), 82(47.9%) mild aGVHD (grade I-II), and 30 (17.5%) no aGVHD (Grade 0). Of 171 patients, 149 (87%) are still alive while 29(17%) died. Among the HLA alleles, t he presence of HLA-Al0 was associated with an increased risk of severe aGVHD (p=0.007) while the presence of HLA-Al9 (p=0.01) and HLA-DR3 (p=0.04) were associated with a decreased risk.HLA-DR9 showed a negative association with the occurrence of aGVHD(p=0.05).Severe aGVHD in older patients (mean age=6.8 years) was significantly higher (p-0.05) than younger patients (mean age =5.9 years). Duration of engraftment (ANC>500) and consumption of packed RBC and platelet concentrates in patients with severe aGVHD decreased (p=0.02) and increased (p=0.000, p=0.009),respectively. We have not found significant association between ABO mismatch, sex mismatch, transplanted nucleated cell dose, and class of thalassemia with severe aGVHD. Conclusion: In this study we suggest HLA-Al0 and age as the risk factors associated with severe aGVHD while HLA-Al9 and HLA DR3 were found to be protective factors against severe aGVHD. Also, HLA-DR9 may have protective effect on aGVHD occurrence.
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Pretransplant serotherapy with campath antibody or antithymocyte globulin prevents severe acute graft-versushost disease following unrelated donor tranplantation using peripheral blood stem cells E. Das-Gupta, J. Byrne, B. Davey, N. Russell (Nottingham, UK) Pre-transplant serotherapy with Campath or ATG is highly effective in the prevention of acute and chronic GVHD following unrelated donor transplantation using BM. PBSC have been associated with an increased risk of acute and chronic GVHD when used for allogeneic transplantation from sibling donors. We have compared the results of unrelated donor PBSCT with BMT undertaken at a single centre since 1996. The study population consisted of 70 patients with acute leukaemia in remission or CML in chronic phase, 46 receiving BM (20 CML, 19 AML, 7 ALL) compared to 24 receiving PBSC (9 CML, 10 AML, 5 ALL). All received conditioning with TBI 14.4 Gy and cyclophosphamide (60 mg/Kg x 2) The CML patients also received ATG (thymoglobuline, Sangstat), 150 mg/day, days -5 to -1 and the AML/ALL patients received Campath 1G or 1H, 10 mg/day, days -5 to -1. GVHD prophylaxis was with cyclosporin A and methotrexate (on days +1, +3 and +6). The median age of patients undergoing PBSCT, (41.6 yr, range19.7 to 58), was significantly older than patients undergoing BMT (30.7 yr, range 16.4 to 50.1, p = 0.003). BM recipients received a median of 2.15 x 10^6 /kg (0.86 -5.4 x 10^6/kg) CD34+ cells compared to 6.44 x 10^6 /kg (2 -18.6 x 10^6/kg) for PBSC. In 28/40 (70%) BMT cases where CMV status was recorded either the donor, the recipient or both were CMV positive compared to 14/24 (58%) S131 PBSC cases (p = 0.42). Overall 3/70 patients failed to engraft including 2 patients receiving BM and 1 receiving PBSC. The median times to engraftment of neutrophils to 0.5 x 10^9/L were 15 (12-26) and 13 (11-20) days for BM and PBSC respectively (p < 0.001). The median times to engraftment of platelets to 50 x 10^9/L were 25 (range 15 to 96) and 14 (range 9 to 110) days for BM and PBSC respectively (p = 0.017). Grade I/II acute GVHD developed in 11/45 (22%) and 12/21 (57%) (p=0.013) and chronic GVHD in 8/36 (22%) and 7/19 (37%) (p=0.341) evaluable patients in the BM and PBSC groups respectively. No patients in either group developed grade III or IV acute or chronic GVHD. TRM at 1 year was 25.4% in the BM group and 24% in the PBSC group. Overall survival at 3 years was 60% in the BM group and 61% in the PBSC group (p=0.713) and was unaffected by age or CD34+ cell number infused. We conclude that pre-transplant antibody therapy with ATG or Campath 1G/1H is highly effective in preventing severe acute GVHD and chronic GVHD following unrelated donor transplantation when using PBSC as for BMT.
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Anti-CD20 monoclonal antibody in the treatment of patients with refractory chronic graft versus host disease
The treatment of extensive chronic graft versus host disease (cGVHD), which occurs in approximately 50% patients treated with allogeneic stem cell transplantation (SCT) from HLAidentical donor, still stands as a great problem. In the base of most various clinical manifestations of cGVHD (sicca syndrome, polyserositis, obstructive lung disease, liver dysfunction, lesion of haematopoietic tissue, scleroderma) is a model of induced connective tissue disease. Dysregulation of B cells (promoted by Th2 cytokines produced by CD4+ donor cells) are responsible for abnormal autoantibodies production to several cell antigens, with consequently autodestruction of tissues. Rituximab (anti-CD20 chimeric monoclonal antibody) is highly effective for in vivo depletion of B cells and might be used in the treatment of autoimmune diseases, such as cGVHD, but its efficacy in this entity is not jet well defined. From December 2001. to April 2002. four patients with extensive cGVHD were treated with rituximab. Median age was 26 years (18-48), 4 male, 1 female, 2 with ALL and 2 with AML. All patients were conditioning with busulphan-cyclophosphamide 2 and received unmanipulated suspension of stem cell (source: 3 pts. peripheral blood, 1-bone marrow) from sibling identical donor. Despite prophylaxis against GVHD (methotrexate, cyclosporine A and methylprednisolone) all 4 pts. developed acute GVHD 1-20.Clinical manifestations of extensive cGVHD refractory to standard immunosuppressive therapy (mycophenolate, cyclosporine A, azathioprine…) were: sicca syndrome (4 pts), obstructive lung disease (4), scleroderma (2), liver dysfunction (2) and thrombocytopenia (2). All patients received rituximab 375 mg/m2 in period from 8 to l2 weeks. During the first week from initial dose of rituximab we registered subjective and objective improvement: decrease of sicca syndrome symptoms, normalization of liver and lung functions and increase of platelet count. One patient, in fourth week from initial dose, had a bacterial lung infection. Preliminary results of use rituximab in the treatment of extensive cGVHD, refractory to standard immunosuppressive therapy, are encouraging, but these results had to be confirmed by further studies.
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Acute GVHD is associated with elevated sIL2R, IL-10 and IL-5 D. Wolff, B. Steiner, C. Zingler, S. Wilhelm, Y. Lazar, C. Kahl, M. Leithaeuser, G. Hartung, J. Casper, M. Freund (Rostock, D) Acute GVHD (aGVHD) has been regarded as a Th-1 mediated immunreaction caused by alloreactive cells of the graft. The role of Th-2 cytokines in aGVHD is less well established. Therefore we evaluated the association of IL-10, IL-5, sIL-2R and TNFalpha with the clinical course following allogeneic hematopoetic stem cell transplantation (HSCT). Patients and methods: 31 patients (age 18-62 years) with allogeneic HSCT after conventional (n=18) or toxicity reduced (n=13) conditioning regimen for hematologic malignancies were evaluated for serum concentrations of sIL-2R, IL-5, IL-10 and TNF before the start of the conditioning regimen, on days -1, 3, 8, at time of engraftment and start of GVHD. The clinical diagnosis of aGVHD was confirmed by histology. GVHD prophylaxis consisted of Cyclosporine A (CsA) alone (n=6), CsA + MTX (n=20), CsA + MMF (n=5). Primary treatment of aGVHD consisted of 2mg/kg Methylprednisolone (MP). Results: 8 patients had no signs of GVHD, 23 patients developed aGVHD (grade I-II n = 17, grade III-IV n = 6). Acute GVHD started at median on day 16 (9-105). At time of diagnosis of aGVHD patients with clinical grade I -II presented with an elevated IL-5 (median 23,8 pg/ml, range <0,01 -110), IL-10 (median 15pg/ml, range <5-113), sIL-2R (median 3121U/ml, range 1341-13974) and varying concentrations of TNF (median 9,5pg/ml, range <4-29,7). Patients without GVHD had in all but one patient no elevated IL-5 (median <0,01pg/ml, range <0,01-85,1), no elevated IL-10 (median 6,5pg/ml, range <5 -16,7), no significant elevated TNF (median 8,45pg/ml, range <4-14,8) and varying concentrations of sIL-2R (median 2594U/ml, range 1346-14826). The differences of the IL-5 concentration between patients with and without aGVHD were statistical significant (p =0,059). Patients with aGVHD grade III-IV presented with the highest elevation of IL-5 (median 93,6 pg/ml, range 6,5-159), a significant elevated TNF (median 16,9pg/ml, range 9,2-50,9) and IL-10 (median 42,4pg/ml, range <4-441). sIL-2R remained with 3518 U/ml at the same level (range 2267-13056) compared to patients with mild aGVHD. The type of conditioning regimen did not effect concentrations of TNF, IL-2R, IL-10 and IL-5 at onset of aGVHD or time of engraftment. Discussion: Although aGVHD has been mainly associated with a Th-1 response our data show a close association not only with sIL-2R but also with the Th-2 cytokines IL-10 and IL-5. Moreover IL-5 and TNF correlated closely with severity of aGVHD.
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Potential significance of IL-6 gene polymorphism and expression as a prognostic tool in hematopoietic stem cell transplantation M. Zaraiski, N. Mikhaylova, A. Afanasyeva, O. Goloschapov, L. Zubarovskaya, B. Afanasyev (St. Petersburg, RUS) Background: Interleukin-6 (IL-6) may be important for development of severe hematopoietic stem cell transplantation (HSCT) complications, e.g., acute graft-versus-host disease (aGvHD) and post-transplant infections. IL-6 production has been shown to correlate with a biallelic C/G polymorphism at the position -174. Methods: We investigated twenty-one donor/recipient pairs who underwent HLA-matched HSCT. Genomic DNA was isolated from peripheral blood leukocytes (PBL), and C/G-174 promoter variants for IL-6 gene were detected by means of allele-specific PCR. Moreover, time-dependent shifts in IL-6 mRNA expression were analysed in five HSCT cases (up to d+30) using common RT-PCR, with total leukocyte RNA as starting material. Results: The incidence of different IL-6 genotypes was 52%, 34% and 14% for C/G, G/G and C/C, respectively. Hence, PCRbased technique for IL-6 allele polymorphism detection proved to be a sensitive method for post-BMT chimerism evaluation in cases of different allelotypes in donor and recipient. Thus marker of chimerism was informative in 34% of HSCT pairs. Meanwhile, we have not found strong correlations between high-producer IL-6 genotype (G/G) and clinical signs of aGvHD. However, the levels of IL-6 mRNA dropped significantly during conditioning regimen, especialy if cyclosporine A was included. Significant increase of IL-6 mRNA was observed in cases of aGvHD. Conclusions: Our preliminary study showed that neither donor, nor recipient IL-6 polymorphisms were associated with occurrence of acute GvHD. IL-6 genotyping could be used as a sensitive method for donor chimerism assessment for, at least, one-third of HSCTs. Interestingly, semiquantitative detection of IL-6 mRNA may allow more accurate evaluation of conditioning efficiency, as well as prediction of acute GVHD.
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One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation A. Mengarelli, A.P. Iori, A. Romano, R. Cerretti, L. Cerilli, M.S. De Propris, S. Fenu, M.L. Moleti, L. De Felice, G. Girelli, W. Arcese (Rome, I) Background and Objectives: Chronic graft-versus-host disease (GVHD) remains the most common late complication of the allogeneic stem cell transplantation, producing significant longterm morbidity and contributing to a substantial risk of late mortality. Chronic GVHD may be more common, more protracted and less responsive to current treatment after peripheral-blood stem cell (PBSC) than bone marrow transplantation. Purpose of this retrospective cohort study was to determine whether the hazard of extensive chronic GVHD after allogeneic PBSC transplantation could be decreased by prolonging cyclosporine A (CsA) prophylaxis over 12 months. Design and Methods: Fifty-seven consecutive patients with hematological malignancies PBSC-transplanted from an HLAidentical sibling were evaluable for chronic GVHD. All patients began the CsA taper at day 50 but 2 different lengths of immunosuppression were used: the first 36 patients were allocated to receive a 6-month course with a taper by 5% at weekly interval (group A), while the following 21 a 12-month course with a taper by 5% every 2 weeks (group B). Results: The cumulative incidence of the extensive chronic GVHD at 2 years was 69% (95% CI, 53-85%) for group A and 25% (95% CI, 3-47%) for group B with an hazard in group B significantly lower than in group A (HR=0.2; 95% CI, 0.07-0.57; p=0.0009). In multivariate analysis, the 12-month CsA taper schedule was significantly associated with a decreased risk of extensive chronic GVHD (HR=0.18; 95% CI, 0.05-0.61; p=0.006). The hazard of transplant-related mortality, relapse and failure to survive in remission was not significantly different among the 2 groups. Interpretation and Conclusions: One-year CsA prophylaxis seems to be more effective than the standard six-month CsA regimen to prevent extensive chronic GVHD after PBSC transplant from an HLA-identical sibling. Conclusive assessment of the benefits of such a prolonged immunosuppression in terms of better quality of life and minor morbidity requires both a longterm follow-up to evaluate the rates of relapse and secondary tumors and a randomized setting.
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A comparison in IL-10 effect on alloreactive T-cell response between peripheral blood and cord blood X. N. Wang, A. M. Dickinson (Newcastle upon Tyne, UK) Human umbilical cord blood (CB) has been used successfully for stem cell transplantation with a lower risk of graft versus host disease (GVHD). However, the mechanisms behind this phenomenon are still not completely clear. To investigate the IL-10 regulatory effect on the CB alloresponse, primary mixed lymphocyte cultures (MLC) were set up with a range of exogenous IL-10 (0, 5, 50, 100 U/ml) using CB and adult peripheral blood (PB) as paired responders against the same HLA mismatched unrelated stimulator PB. MLC primed responder cells were tested for allo-specific cytotoxicity against stimulator PHA blasts using a standard 51Cr release assay. The proliferative responses were determined by 3H-thymidine incorporation. The supernatants from primary MLC were tested for TNF-alpha and IFN-gamma levels by ELISA. The results demonstrated that the presence of exogenous IL-10 reduced T cell proliferation and cytokine production in a dose dependent manner in both CB and PB. However, CB cells were more sensitive to IL-10 modulation than PB cells. At an IL-10 concentration of 5U/ml the mean inhibition rates for T cell proliferation, TNF-alpha production and IFN-gamma production were all significantly higher for CB than for PB (54% vs 23%, 67% vs 35% and 81% vs 53% respectively with p values of 0.006, <0.001 and 0.01 respectively). At a concentration of 100U/ml, IL-10 significantly reduced the alloreactive cytotoxic response of both CB and PB effector cells. However, the effect was much greater on CB effector cells than on PB effector cells (p=0.017). The higher sensitivity of CB to IL-10 modulation could be due to the immature status of CB cells and may play a role in inducing tolerance which contributes to reduced incidence and/or severe of GVHD observed after CB transplant.
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Heat shock protein gene polymorphism may indirectly influence theoutcome of alternative hematopoietic stem cell transplantation K. Bogunia-Kubik, A. Lange (Wroclaw, PL) In the present study we analysed whether matching at Heat shock protein (HSP) loci affect the outcome of hematopoietic stem cells transplantation (HSCT). Among 50 patients studied (F/M: 16/34; 39 hematological malignancies, 5 anemias and 6 others), 13 were grafted from haploidentical and 37 matchedunrelated donors. Twenty-two patients received myeloablative and 28 non-myeloablative therapy. In all these patient-donor pairs, in addition to high resolution typing of HLA-DRB1, dimorphism within the HSP70-hom gene +2763 (G/A) was analysed with the use of ARMS technique (Jenkins et al. Tissue Antigens, 2000: 56: 38-44) . HSP-A allele was previously reported to be associated with DRB1*04. Similar tendency was seen in our group of patients. Moreover, in healthy individuals (HSCT donors) DRB1*03 was more frequently detected in GG-positive individuals than those having A allele (AA, AG genotypes) (11/20 vs 6/30, p=0.012). Conversely, DRB1*11 was rarer in HSP-GG+ donors (1/20 vs 10/30, p=0.018). Among 50 patient-donor pairs studied, 1 was mismatched for 1 antigen at DRB1 loci, but matched for HSP alleles, and the patient did not show toxic and GvHD complications. Seventeen out of 49 DRB1 matched pairs were unmatched for HSP70-hom alleles. There was no association between HSP mismatching and development of toxic lesions and aGvHD (0.60 vs 0.53 and 0.18 vs 0.25, ns for grade II-IV toxic and aGvHD complications in HSP mismatched vs matched pairs, respectively). This lack of relations between HSP mismatching and manifestation of post-transplant complications was independent of conditioning regimen (myeloablative and non-myeloablative). Patients a nd donors showed similar distribution of HSP70-hom alleles. A tendency was observed towards the higher incidence of grade II-IV aGvHD in patients carrying GG genotype (0.35 vs 0.17, ns). Moreover, patients transplanted from DRB1*03 positive donors with HSP-GG genotype more frequently developed grade III-IV toxic complications and aGvHD grade >= I than those grafted from donors carrying HSP-GG and other DRB1 specificities (0. 
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Psolaren and ultraviolet A irradiation as adjuvant treatment of chronic extensive graft-versus-host disease in adults P. Mensah, A. Wojas-Pelc, D. Hawrylecka, A.B. Skotnicki (Krakow, PL) Psolaren is a photosensitizer and when used with ultraviolet A (320-400 nm wavelenght) provides effective therapy for a number of dermatological diseases postulated to have an immunologic pathoghenesis. Published results of preliminary trials using Psolaren and Ultraviolet A irradiation (PUVA) to treat acute and chronic graft-versus-host disease (GVHD) have demonstrated encouraging results. Patients and methods: 6/27 patients (4 F, 2 M; median age: 34) after matched related allogeneic hematopoietic cell transplantation (4 PBSCT, 2 BMT) developed chronic extensive GVHD with 100% skin involvement and 3/6 had combined (liver) involvement as well. They were subjected for transplantation because of CML I CP (2), AML CR1 (2), ALL (CR1) 1 and primary resistant ALL B-cell (1). GVHD prophylaxis consisted of cyclosporine and methotraxate (2/6 short course). In 2 of 3 patients acute GVHD (grade 1 and 2 respectively, treated with methylprednisolon at dose 1 mg/kg b.w. every 12h) preceded development of chronic extensive GVHD. Diagnosis of chronic GVHD was confirmed clinically and histopathologicaly. After mean time of 5-21 days of ineffective treatment in regard to skin changes with systemic treatment (prednison/methylprednisolon plus cyclosporine A, prednison / MMF) patients were qualified to PUVA therapy. 30 mg of Oxsolaren was given orally 1 hour before irradiation. As a source of ultraviolet A radiation Waldman Lichttechnik UVA (Germany) lamp was used. Initial radiation dose was 0.5 J/cm2 for session. Procedure was performed three times per week in further radiation doses adjusted by dermatologist according to patient's skin type and individual local reactions to irradiation. The PUVA was continued up to 3-6 months. Results: all 6 patients (100%) showed a satisfactory, rapid (1-4 weeks) and complete clinical response of their skin disease. 3/5 pts. showed the decrease of the cholestatic liver enzymes (GGTP, FA, LDH). Side effects consisted of mild, persistent nausea (one case) and phototoxic erythema (three cases) and were not considered by patients as worsening life-quality. No infectious episodes occured through the PUVA therapy. Conclusions: PUVA as adjuvant treatment to standard therapy seems to be an effective and well tolerated therapy for patients affected by chronic resistant GVHD. In our limited experience PUVA did promising regression of serious skin changes caused by chronic GVHD.
P554
Cytokine profiles in bone marrow transplantation R. Lunn, N. Sumar, A. Bansal, J. Treleaven (Carshalton, Sutton, UK) Graft-versus-host disease(GVHD) is a severe illness complicating up to half of all patients undergoing bone marrow transplantation (BMT). Many studies have attempted to define factors predictive of GVHD beyond the influence of the degree of histocompatibility. Cytokines and growth factors secreted by donor and host cells are thought to play a pivotal role in GVHD. The aim of this work was to investigate whether changes in serum levels of soluble IL-2 receptor (CD25), tumour necrosis factor-alpha (TNF-a), transforming growth factor-beta (TGF-b), vascular endothelial growth factor (VEGF) and soluble Fas may assist in the early detection of GVHD in patients undergoing bone marrow transplantation. The serum cytokine levels of 75 patients were determined using enzyme-linked immunosorbent assays and an Immulite analyser. Patients were divided into three groups; those that received autografts (n=34), those that received allografts (n=28) and those that received no grafts (n=13). Sera from healthy controls were included in the study. CD25 and sFas levels were significantly raised in all the patient groups compared to controls, but no statistical difference was found within the three groups of patients for these two cytokines. TNF alpha was raised in the three groups compared to controls but only reached significance in the allograft group (p=0.007). There was a significant difference in TNF alpha when the allograft group was compared to the no transplant group (p=0.022). No difference was found in the levels of TGF beta for any of the groups. Serum levels of VEGF were decreased in the autograft and allograft patients compared to controls with a significant difference found in the autograft group (p=0.007). VEGF levels were significantly lower in the autograft group compared to the allograft group (p=0.004) and also in the autograft group compared with the no transplant group (p=0.011). The allograft group divided into patients that developed GVHD and those that did not, confirmed serum VEGF levels to be significantly higher in those with GVHD (p=0.042). BMT is associated with immune activation that is greater with increased histoincompatibility. Additionally, these results suggest that VEGF may be associated with GVHD and could be a useful marker in detection of GVHD. The risk of relapse is significantly lower in patients who develop graft-versus-host-disease (GVHD) but the mortality associated with GVHD reduces the potential benefit. To identify if clinical GVHD is essential for long-term disease free survival after allograft we compared 131 patients (M: 80, F:51; median age: 35 yr. range: 4-62) who received autograft for AML with 32 patients (M:16, F:16; median age: 19.5 yr., range: 4-48) who received allograft and never developed clinical acute or chronic GVHD. All patients were in CR1, conditioned with TBI, had marrow for rescue, sibling donor for allograft. The dose of TBI was 9.5Gy (n=24), 10.5Gy (n=135) or 11.5 Gy. (n=4) and there were no differences in two groups. TBI was used with melphalan (n=136) or Cyclo (n=27). GVHP was CyA alone (n=20) or with Mtx (n=9) and 3 received other agents but no patient had TCD. Allograft patients had significantly faster recovery of ANC>0.5x109/L (16 d vs. 33 d, p<0.0001) and the platelet recovery>50x109/L (20 d vs. 88 d, p<0.0001). There was trend toward lower relapse risk in allograft patients (9/32 vs. 52/131, p=0.07). The overall survival was significantly better for allograft patients (5yr. probability 63% vs. 46%, p=0.018). Event free survival was significantly better for allograft patients (5yr. probability 60% vs. 42%, p=0.017). There was no statistically significant difference in the incidence of TRM in two groups, although percentage of autograft patients experiencing TRM was higher than allograft patients (3/32, 9.4% vs. 21/131, 16%, p=0.26). In multi-variate analysis only allograft was associated with significantly better overall survival (RR: 2.1, 95% CI: 1.12-3.92, p=0.021) and event free survival (RR: 2.02, 95% CI: 1.1-3.72, p=0.023). No factor was independently associated with risk of relapse or the risk of TRM. This single centre analysis shows that as compared to autograft for first remission AML, overall survival and event free survival are better for allograft patients. Even though the risk of relapse appears to be same, the percentage of patients who relapse after allograft is significantly lower even if they do not develop clinical GVHD. This is likely to be related to reduction in TRM in absence of GVHD as well as the fact that development of clinical GVHD may not be essential for GVL effects. This analysis suggests that better understanding of GVHD mechanisms and development of drugs for effective prevention of this complication is urgently required.
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No effect of HLA-DPB1 matching, but HLA-DPA1 compatibility has influence on relapse and survival in unrelated stem cell transplantation M. Schaffer, M. Remberger, O. Ringdén, O. Olerup (Stockholm, S) Matching for HLA-A, -B, and DRB1 alleles is known to be of importance for the outcome in unrelated stem cell transplantation. However, the role of matching for HLA-DPB1 and -DPA1 is still not clear. It has been reported that patients mismatched for two DPB1 alleles have an increased rate of graft versus host disease (GVHD) and reduced patient survival. The aim of this study was to see if matching for these loci had any correlation to the clinical outcome considering GVHD, relapse and survival. Allele level typing for all classical HLA loci was performed using PCR-SSP. Seventy-six patients who received stem cell grafts at Huddinge University Hospital and their unrelated donor were investigated. This is a single center study with uniform protocols for pre and post transplant treatment. A majority of the patients were treated for a malignant disease (65/76). The pairs were characterised by allele level identity for HLA-A, -B, -C, -DRB1 as well as for -DRB3, -DRB4, -DRB5, -DQA1 and -DQB1. Only 22% of the pairs were matched for both HLA-DPB1 alleles. Fifty-nine percent had one HLA-DPB1 mismatch and 18% had two DPB1 incompatibilities. In contrast to other reports no differences concerning GVHD, relapse or survival comparing the groups with either two, one or zero mismatches were observed. We have also studied the effect of matching for HLA-DPA1. Thirty-five patients (46%) received DPA1 mismatched stem cell grafts. No difference in acute GVHD grades II-IV or grades III-IV were seen. However, the patients with disparities for DPA1 had decreased survival rates and tended to have increased frequency of relapses, 62% vs 3 2% for the HLA-DPA1 compatible pairs. We have previously reported that matching for DPA1 was correlated to increased survival in HLA-A, -B and -DRB1 matched pairs. In this partially overlapping group of patients receiving A,B,C,DRB,DQA1,DQB1 fully matched stem cell grafts, the same observation on the importance of matching for the DPA1 loci is made. This is a single center report of an influence of DPA1 compatibility on survival in unrelated SCT and this observation needs to be addressed also in other groups of patients.
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Inolimomab in the treatment of acute graft-versus-host disease N. Dhédin, J.-O. Bay, J.-P. Vannier, M. Michallet, M. Goerner, R. Tabrizi, C. Faucher, F. Garban, C. Leyronnas, J.-P. Jouet, N. Milpied, A. Stamatoullas, C. Galambrun, J. W ijdenes, F. Kwiatkowski, A. Zinaï, A. Fischer (Paris, Clermont Ferrand, Rouen, Lyon, Pessac, Marseille, Grenoble, Lille, Nantes, Besançon, Dardilly, F, Heidelberg, D) From June 1998 to October 2002, 101 patients received inolimomab for the treatment of acute GvHD (aGvHD) following allogeneic hematopoietic stem cell transplantation (HSCT) in 14 institutions. Data are currently available for 73 patients. Median age, at transplantation, was 32.5 years (2 months-61 y). Initial disease was: immune deficiencies (17 patients), leukemia (36 patients), NHL (5 patients), other hematological malignancies (10 patients), solid tumors (5 patients). Thirty seven patients received HSC from HLA-matched sibling donors, 25 from unrelated HLA-matched, 7 from mismatched unrelated donors and 4 from related mismatched donors. Forty two patients received BMT, 27 PBSCT, 1 DLI (following PBSCT) and 3 cord blood transplantation. Conditioning regimen was myeloablative for 62 patients and non-myeloablative for 11 patients. Sixty four patients received ciclosporine for GvH prophylaxis, combined with methotrexate for 41 patients. One patient received methotrexate alone. Prophylactic ATG was administered to 3 patients, MMF to 4 patients. Eight patients received CD34+ -selected HSC. Acute GvHD was diagnosed at a median of 28 days (9-96 d) after HSCT (grade I for 3 patients, grade II for 21, grade III for 24 and grade IV for 25). Initial treatment of aGvHD was steroids 1 to 7 mg/kg/day. Inolimomab was administered for steroid-resistant aGvHD at a median of 15 days (2-97 d) after onset of aGvHD at a median dosage of 0.31 mg/kg/day (0.1-1.4 mg/kg/d) during a median period of 19 days (5-97 d). Results: Preliminary results of available data showed 18 complete responses (CR), 27 partial responses (PR), and 27 non responses (NR). Overall response rate was 62%. In a multivariate analysis, transplantation for non-malignant diseases, myeloablative conditioning regimen and grade III-IV aGvHD appeared to be associated with a better response to inolimomab. No unexpected adverse event has been notified, so far. To date, thirty six patients are alive, with ten of them surviving more than 12 months. Thirty seven have died. Survival is significantly related to response to inolimomab (p=0.0003): at nine month-follow-up, survival rate is 60.3% for responders compared to 18.7% for non responders. Conclusion: Inolimomab seems to be effective in the treatment of severe steroid resistant aGvHD, both in pediatric and adult populations. A better knowledge of the pharmacokinetic and, hence, the dosage of inolimomab are warranted. Further data on additional patients will be presented.
P558
Cytotoxic and helper precursor T-cell frequencies are not predictive for the outcome after stem cell transplantation when analyzed from the respective graft B. Kircher, D. Niederwieser, A. Gächter, K. Lätzer, A. Mitterschiffthaler, G. Gastl, D. Nachbaur (Innsbruck, A; Leipzig, D; Vienna, A) Despite improvements in human leukocyte antigen (HLA)-typing graft-versus-host disease (GvHD) remains an important major complication after allogeneic hematopoietic stem cell transplantation (SCT). Cytotoxic and helper T lymphocyte precursor (CTLp and HTLp) assays have been used by a number of investigators as a predictive model for incidence and severity of GvHD after HLA-identical sibling or unrelated bone marrow transplantation (BMT) with conflicting results. The reason for this may be that CTLp and/or HTLp were measured in the peripheral blood (pb) of the donor but not in the respective type of g raft, i.e. BM or granulozyte-colony-stimulating factor (G-CSF)-mobilized pb. We have assessed whether or not the CTLp and HTLp assay can predict the outcome after HLA-identical SCT when the precursor frequencies were analysed in the transplanted graft. The host-specific CTLp frequencies measured from 26 patients were very low in all stem cell sources (1/212380±48125 for pb, 1/299101±106541 for BM and 1/337908±90607 for G -CSFmobilized pb (p<0.05 against pb)). As positive control responder cells were tested against HLA-mismatched unrelated third party cells. They were high in all stem cell sources (1/6702±1580 for pb, 1|3111±1027 for BM, 1/13657±3567 for G-CSF-mobilized pb, respectively). The host-specific HTLp frequencies determined from 7 patients were also very low in all stem cell sources (1/1336673±428659 for pb, 1/1123694±174120 for BM and 1/1479903±1344288 for G-CSF-mobilized pb, respectively) and the third-party-specific HTLp frequencies high (1/27299±8855 for pb, 1/15406±5168 for BM and 1/72158±16097 for G -CSFmobilized pb, respectively). No correlation was observed between CTLp and HTLp frequencies assessed in the respective stem cell sources and the occurrence of acute GvHD, chronic GvHD and relapse. The lower third-party-reactive cells in the G-CSF-mobilized pb (p<0.05 against pb) indicate that the mobilization procedure itself (skewing of T cells towards a different phenotype) may influence the results. In conclusion, we did not find a predictive value of CTLp and HTLp frequencies for the outcome after HLA-identical SCT when measured in the graft.
P559 In vitro immunosuppressive activity of monoclonal anti-CD25 antibodies B. Kircher, K. Lätzer, G. Gastl, D. Nachbaur (Innsbruck, A)
Graft-versus-host disease (GvHD) remains a major complication after a llogeneic hematopoietic stem cell transplantation (SCT). Monoclonal antibodies (mAb) directed against the interleukin-2 (IL-2) receptor alpha-chain, CD25, are promising alternative immunosuppressive drugs because of their narrow specificity and low toxicity. We therefore analyzed the in vitro activities of the chimeric anti-CD25 mAb basiliximab and the humanized anti-CD25 mAb daclizumab in different test systems for their effect on alloimmune response and T -cell activation in comparison to cyclosporine A (CsA) and prednisolone. Anti-CD3-and alloantigen-induced T -cell proliferation were significantly decreased in a dose-dependent fashion. By addition of exogenous IL-2 at concentrations which stimulate T -cell proliferation the reduction in T-cell proliferation induced by the anti-CD25 mAb could be abrogated. The combination of mAbs and CsA in suboptimal concentrations resulted in a synergistic anti-proliferative effect on anti-CD3-and alloantigen-induced Tcell proliferation. Anti-CD25 mAbs also inhibited the generation of antigen-specific cytotoxic T-lymphocytes in a limiting dilution assay whereas they had no effect on the lytic activity of established antigen-specific T-cell clones. This in vitro study demonstrates a strong immunosuppressive activity of both chimeric and humanized mAbs against CD25. The synergistic activity with CsA justifies the early use for prevention rather than treatment of GvHD.
P560
The level of IL-1 beta and IL-1Ra in MLR supernatants is associated with the incidence of acute GVHD following HLAmatched sibling BMT H. Cullup, X.N. Wang, A.M. Dickinson (Newcastle-upon-Tyne, UK) The mixed lymphocyte response (MLR) is used for the primary generation of alloreactive CTLs which are subsequently cocultured with patient skin in the in vitro skin explant assay, utilising patient skin as an alloreactive predictive readout of GVHR. The culture supernatant from the MLR contains cytokines including the pro-inflammatory cytokines IL-1 alpha, IL-1 beta and their naturally occurring receptor antagonist IL-1Ra. The IL-1 family has been implicated in the inflammatory process of GVHD. The IL-1 family of cytokines were measured and compared to the grade of GVHR (EBMT 2002 abstract) and acute GVHD following BMT. MLR were carried out on 31 HLA-matched sibling BMT patient donor pairs. This BMT cohort included both myeloablative and mini-transplant conditioning regimens with T cell replete grafts. 1 x 10(6) cells of stimulator and responder cells/ml were cultured for 7 days at 37 ºC with 5% CO2. The supernatants from these cultures were frozen at -80 ºC prior to cytokine measurement. A paired antibody ELISA was used to detect IL-1 alpha and IL-1Ra. IL-1 beta was measured using an ELISA set. The data was analysed with respect to acute GVHD following transplant by non-parametric statistical analysis due to a skewed non-Gaussian distribution. There was no significant difference between incidence and severity of aGVHD with supernatant IL-1alpha levels. There was a significant difference with the incidence of aGVHD with both IL-1 beta and IL-1Ra levels in the MLR supernatants. The level of IL-1 beta was lower in the MLR supernatants of transplants without aGVHD compared to those with grades I-IV (p = 0.0058). The level of IL1Ra was highest in MLC supernatants where there was no aGVHD compared with grades I -IV (p = 0.0115)(see figure  below) . The level of IL-1Ra in the grade 0 aGVHD group could not be attributed to possession of allele 2 in the donor IL-1Ra VNTR genotype. The differential production of agonist and antagonist in the MLR supernatant illustrates the regulation of the IL-1 family in the immune response. Measurement of the IL-1 family in MLR cultures may aid in the prediction of aGVHD in sibling BMT. The cohort of transplants analysed included those given increased GVHD prophylaxis after the prediction of aGVHD by the in vitro skin explant assay, where the majority of this increased immunosuppression targeted donor T cells. These results further illustrate the role of monokines in aGVHD pathology.
P561
The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease E. A. Soydan, M. Arat, P. Topcuoglu, M. Ozcan, O. Arslan, R. Idilman, G. Gurman, M. Beksac, H. Akan, O. Ilhan (Ankara, TR) The use of systemic or topical corticosteroid and/or calcineurin inhibitors such as cyclosporin-A and tacrolimus are initial treatments for chronic graft versus host disease (cGVHD). Because of some severe adverse effects of these drugs on immuno-comprimised hosts, and alternative immunosuppressive drugs are investigated Mycophenolate mofetil (MMF) is one of these alternative drugs which shows its immunosuppressive effect by inhibition of T and B cell proliferation. Depending on its efficacy on solid tumor rejection it has been used for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation. We evaluated the efficacy and safety of MMF on treatment of patients with progressive and refractory cGVHD in a retrospective analysis. Between August 1998 and December 2002, 20 out 7 0 patients with steroid and CSA refractory or dependent chronic GVHD received MMF, starting with a dose of 15mg/kg/day per oral and gradually increased to maximum 2-3gr/day if there was no response, median 10.5 (4-22) months with other immunosupresive drugs. Median age was 37 years (9-48 years). Diagnoses were 8 AML, 12 CML and 1 MM. Seven patients had de novo cGVHD while all the others had progressive cGVHD. Except 3 patients who had limited liver cGVHD, all patients had extensive involvement, 9 likenoid and 6 sclerodermeoid biopsy proven skin involvement and 6 patients with bronchiolitis obliterans. In eight patients including 3 patients with limited liver cGVHD, there was complete response so all the other immunosuppressive drugs were reduced and stopped (%40). Four patients had stable disease after adding MMF to their treatment and received MMF in combination with other immunosuppressive agents (%20). Remaining 8 patients had progressive disease and underwent additional immunosuppressive therapies such as extracorporeal photoimmunotherapy (%40). No severe adverse event was observed in patients other than nausea, vomiting and diarrhea in two patients of whom MMF dose was reduced in one and stopped in the other. With this evaluation we recommend MMF as an effective and safe immunosuppressive agent for cGVHH with acceptable side effects but the optimal time for the use of MMF and duration of treatment, best indications and combinations are still necessary.
P562
Extracorporeal photoimmunotherapy for treatment of steroid refractory extensive chronic graft versus host disease: Turkish experience O. Ilhan, S.B. Kalayoglu, A. Ünal, M. Arat, Ö. Arslan, D. Sargin, M. Cetin, E. Ayyildiz, M. Özcan, G. Gürman, M. Beksac, H. Akan (Ankara, Istanbul, Kayseri, TR) Chronic graft versus host disease (GVHD) can arise as a late complication after allogeneic hematopoietic cell transplantation. Patients with extensive disease to date require intensive early and long-term immunosupression. We aimed to share our centers' experience using Extracorporeal photoimmunotherapy (ECP) in this complicated patient population. Thirteen patients in three centers were treated with ECP (UVAR XTS) on 2 consecutive days every 4 weeks until resolution of GVHD over a period of 6-15 months. Beyond extensive cutaneous CGVHD, four patients had also bronchiolitis obliterans (BO). Skin scores assessed by experienced dermatologist and laboratory and radiological findings after 4 months of ECP were response criteria. ECP was tolerated excellently only one patient developed Gr4 thrombocytopenia and another patient had a massive GIS bleeding due to a Mallory-weiss tear. In this almost fully automated system mean 261.4 ml buffy-coat was processed within 193 min using UVADEX sterile solution. After a median of 12 cycles of treatment, all patients showed a favorable response. Reduction in cholestatic parameters was observed in 9, improvement in respiratory functions and CT evaluations in 4, and reduction in immunosuppressive agent need in 10 patients. The most impressive result was the reduced need for hospitalization of these patients and improvement of skin lesions. All but one of the skin biopsy scores were also better after ECP. As chronic extensive GVHD is a life devastating disorder, every attempt to improve the quality of life should be evaluated carefully. Our findings suggest that ECP is a safe and effective adjunctive therapy for steroid refractory chronic extensive GVHD of the skin. The place of ECP for the treatment of visceral GVHD and additional co-morbid conditions like BO should be further analyzed in large scale trials.
P563
Is there a CD34+ threshold of infused cells that influences the clinical outcome after non-myeloablative allogeneic peripheral blood stem cell transplantation? A.S Michallet, F. Nicolini, Q. Lé, A. Thiébaut, C. Audigier-Valette, X. Thomas, J. Troncy, C. Vigouroux, J.P Bourgeot, A. Eljafaari, M. Michallet (Lyon, F) Peripheral blood (PB) has been increasingly used as a source of CD34+ hematopoietic stem cell (HSC) in allogeneic transplantation. It was shown in conventional allogeneic transplantation, that a dose of 8.106 CD34+/kg infused was associated with increased incidence of chronic GVHD and improved disease-free survival. Regarding non-myeloablative transplant, the influence of CD34+ cell dose infused on hematopoietic recovery, on acute or chronic GVHD development and on clinical outcome is until now not well explored. We studied 25 patients (12 males and 13 females) with a median age of 51 years (19-64) undergoing non myeloablative alloperipheral blood stem cell transplantation (PBSCT) from HLA identical sibling donors. Diagnosis were: 7 solid tumors, 6 multiple myelomas, 4 chronic leukemias, 3 acute leukemias, 2 non-hodgkin's lymphomas, 2 myelodysplastic syndromes and one hodgkin disease. Eleven (44%) patients were transplanted in advanced disease and only 6 (25%) in complete remission (CR). The median dose of CD34+ infused in this group was 6.58.106 (3.14-17.33) and in order to study the relevance of the CD34+ cell dose, we analyzed 2 groups of patients : group 1 who received a CD34+ dose < 6x106/kg CD34+ and group 2 a dose > or =6x106/kg. Respectively,in group 1 and in group 2 : a) there were 9 and 15 patients,b) days to ANC> 0.5G/l was 18 and 15,c)No. of days with ATG was 1.5 and 1.5, d) no acute GVHD for 3 (33%) and 7 (47%), acute GVHD I-II : 5 and 7, acute GVHD III-IV : 0 and 2 and chronic GVHD : 3 (33%) and 7 (47%), e)median number of CD3+ (108/kg) was 273.95 and 269.29, f) 9 patients received < 6x106/kg CD34+ cells with 273.95 x108/kg CD3+ cells and 15 patients ³ 6x106/kg CD34+ cells with 269.29 x108/kg CD3+ cells. All patients engrafted, and regarding acute GVHD severity, we did not see any grade III and IV in the group 1. All patients were evaluable for chronic GVHD. In group 2, 7 patients developed chronic GVHD (3 extensive) and 3 in the group 1 (all limited). In term of disease response, 3 patients were in CR in group 1 and 7 in group 2. At the last follow-up, 4 patients in group 1 are alive (3 in CR) and 5 in group 2 (4 in CR). The T -cell dose did not influenced GVHD incidence. In conclusion, our analysis shows that in non-myeloablative PBSCT, a number of CD34+ cell infused < or =6x106/kg seems to increase extensive chronic GVHD incidence and is associated with a better disease response and a worse survival because of chronic GVHD mortality.
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Graft-versus-host disease 'protection' after a partially Tdepleted one HLA haplotype mismatched transplantation in a case of omozygous acute myeloid leukemia E. Todisco, M. Parma, E. Terruzzi, L. Mascaretti, M. Dassi, K. Perruccio, F. Aversa, P. Pioltelli, E.M Pogliani (Monza, Perugia, I) Engrafment and prevention of GvHD have been achieved in recipients of one-haplotype mismatched hematopoietic stem cell transplantation infusing a megadose of extensively T -cell depleted CD34+ cells after immunosuppressive and myeloablative conditioning regimen. Recently, it has been shown that despite the presence of numerous donor antigen-presenting cells (APCs) in the graft, only host's APCs initiate GvHD. We report a case of a 41 years old woman with acute myeloid leukemia in CR II who received a T-cell depleted hematopoietic stem cell transplantation from a haploidentical sibling on june 2002. As the patient is omozygous at HLA-A, B, Cw, DRB1, DQB1, DPB1, the donor-recipient pairs were 5-loci mismatched in the host-vs-graft direction but 0-loci mismatched in the graftvs-host direction. The graft consisted of 16.62 x 106/Kg immunoselected CD34+ cells and 3.73 x 103/Kg CD3+ cells. Engraftment was documented on day 18 but, on day 40, after a CMV infection, the patient developed a severe pancytopenia. To enhance the engraftment, the patient was boosted with 10 x 106/Kg CD34+ cells and 1 x 105/Kg CD3+ cells. Although infusing more than 104/kg CD3+ cells it is above the threshold for GvHD in haploidentical transplants, we expected it would have been safe because of the GvHD "protective" phenotype. Improvement in neutrophil count was documented on day 13 and interestingly, peripheral T lymphocytes normalized six weeks later: 2345/mmc CD3+, 568/mmc CD3+CD4+, 1626/mmc CD3+CD8+ (inversion of CD4+/CD8+ ratio), 1097/mmc CD3-CD16,CD56+ cells. Furthermore, ELISPOT assay on day 40 showed an unexpected good frequency of antigen specific IFN-g-CD8+-producing cells: anti-Aspergillus fumigatus CD8+ cells were 1/2535; anti-Candida albicans CD8+ cells 1/3803 and anti-CMV CD8+ cells 1/4403. Despite the prompt immunologic reconstitution, at 3 months follow-up, the patient hasn't so far developed any sign or symtom of GvHD. We believe that "GVHD protection" is due to the fact that the host is omozygous and thus donor lymphocytes do not recognize any mismatches on recipient dendritic cells. In conclusion this case represent an in vivo demonstration that host-derived APCs initiate GvHD.
P565
HistoCheck: An internet-based software tool for estimating the allogenicity of HLA mismatches H. -A. Elsner, D. DeLuca, J. Strub, R. Blasczyk (Hannover, D) HLA polymorphism is a major barrier for hematopoietic stem cell and solid organ transplantation. To estimate the allogeneic potential between HLA mismatched stem cell donor/recipient pairs, we recently proposed a matching score (dissimilarity index), that is based on structural data of HLA class I molecules, and on functional similarity of amino acids. This first approach revealed new features about presumptive subtype allogenicities within the HLA-A*23 and A*24 groups. However, since the scoring matrix was limited to these two groups, its practical utility was rather restricted. For this reason the extension of the scoring algorithm to other HLA class I allelic groups would be helpful in those clinical settings, when there are several potential stem cell donors who all differ from the recipient by a single HLA class I mismatch. Although in many cases non-HLA factors (cytomegalovirus status, age, gender) will already allow a ranking of donors, in other settings the allogenicity of the HLA mismatch will be the most important player for decision making. Since the advance of HLA class I typing at the allelic level will probably reveal far more subtype mismatches presently not detected, there will be a growing need for additional information on allogenicity of mismatches. Therefore, we have developed an internet-based software tool ("HistoCheck") that is capable to assess the allogenicity (matching score) between any pair of HLA class I alleles, not only on the subtype level, but also with regard to mismatches between groups. Newly described HLA sequences will be regularly integrated into the database according to the updates of the nomenclature for factors of the HLA system. The software is intended to be a first step for estimating the allogenicity of HLA class I mismatches in peculiar clinical settings, as long as there are no reliable in vitro or clinical studies available. The clinical data of the 13th IHWC are currently under evaluation using the HistoCheck algorithm. The algorithm can later be modified according to functional data, e.g. peptide binding specificities. With the extension of the sequence similarity concept to all HLA class I loci, the HistoCheck software may contribute to prevent HLA mismatching being a matter of chance.
P566
Ex vivo purging of canine bone marrow in allogeneic BMT by anti thymocyte globuline W. Guenther, M. Weber, H-J. Kolb (Munich, D) Anti thymocyte globuline (ATG) is often used in transplantation medicine as an immunosuppressant agent for the prophylaxis against a graft versus host disease (GvHD) and in transplant conditioning as an additional drug to deplete T -cells which escaped the radiation and chemotherapy. In our canine model we used canine ATG in order to deplete T-cells out of a bone marrow transplant ex vivo. The ATG (17.6mg/ml) was produced in rabbits using puppy thymocytes and was absorbed against placenta, kidney and erythrocytes. After in vitro experiments (CFU, cytotoxicity-and binding assays) we decide to use a dilution of 1:800. In our GvHD model (homozygous donor and heterozygous recipient) dogs were conditioned only by 10 Gy radiation. ATG was added to the bone marrow harvest in a dilution of 1:800 incubated for 30 minutes at 38° C. A mean of 4x108 of bone marrow mononuclear cells per kg body weight was infused to the recipient one day after radiation. Even a low titre of ATG or rabbit IgG was detectable still 20 days after BMT the recipient did not develop anti rabbit or anti ATG antibodies. In prior experiment where ATG was given in vivo (1mg/kg b.w.) dogs developed antibodies within 8 -14 days after transplantation. Leukocyte recovery was a little bit delayed as a count above 1000/µl was not reached before day 29 post BMT in comparison to day 14 in the control group. Leukocytes increased very rapidly to above 5000/µl on day 37. On the same day we detected the first signs of skin graft versus host disease (GvHD) which was scaled grade II to III. Liver and kidney were not affected. ATG seems suitable for ex vivo depletion of bone marrow in an allogeneic system. Probably a higher dose (1:400 dilution) of ATG might even help to overcome the GvHD problem.
P567
Low dose rabbit anti thymocyte globuline prevents GVHD in sibling allogeneic eripheral blood stem cell transplantation for CML
Our initial experience (from November 1995 to September 1999) with peripheral blood stem cell (PBSC) transplants in 21 patients with CML resulted in an unacceptable rate of extensive cGVHD. For that reason, starting from October 1999 we have added low dose rabbit anti thymocyte globuline (ATG) in the conditioning regimen. We present here a comparison between the two groups. A total of 31 allogeneic peripheral blood Stem Cell Transplants (SCT) from HLA identical sibling donor for CML were performed. Median age was 41 years (range 19-53), 21 males and 10 females. The median interval diagnosis-transplant was 14 months (range 4-59). Conditioning treatment consisted mainly of BU-CY and GVHD prophylaxis was short term MTX+CsA. 10 CML patients received low dose rabbit ATG (15 mg/kg, Fresenius). All patients engrafted and no rejection occurred. Acute and chronic GVHD were graded according to the standard criteria in patients surviving longer than 30 and 90 days after transplant. Grade II-IV acute GVHD developed in 7/21 patients who didn't receive ATG and 2/10 patients who received ATG. cGVHD developed in 15/21 patients without ATG and in 4/10 patients with ATG. In particular we observed 2 extensive cGVHD in the latter cohort (10 patients) and 10 in the former one (21 patients). Five hematological relapses occurred in the no-ATG group (2 in CP 3 in advanced phases) and no relapses in the other goup. The patients were strictly studied at molecular level for the bcr-abl rearrangment after transplants; the incidence of isolated positivity was similar in the two group. Conclusion: even if the number of patients is small and it wasn't a randomized study we suggest that the use of low dose rabbit ATG is effective in decreasing the rate of GVHD in particular extensive cGVHD without increasing the risk of relapse.
P568
Calcineurin activity as a therapeutic index of immunosuppression: a functional, pharmacodynamic approach for GVHD prophylaxis S. Sanquer, M. Schwarzinger, S. Maury, K. Yakouben, C. Pautas, M. Kuentz, R. Barouki, C. Cordonnier (Paris, Creteil, F) Introduction : Despite a prophylaxis based on the association of cyclosporin (CsA) and methotrexate (MTX), more than 50% of the recipients of allogeneic stem cell t ransplantation (SCT) develop grade>II acute graft-versus-host disease (GVHD) that will be lethal for 10 to 20% of them. We have recently shown, in a pilot study, that a poor inhibition of calcineurin activity (CNA) under CsA therapy was associated with the onset of acute GVHD during the first two months of allogeneic SCT. This pilot study was continued for a supplementary year in order to further investigate our findings. Methods : 31 allogeneic SCT recipients were enrolled during a 21-month period. All received GVHD prophylaxis with CsA (2 mg/kg/day) and methotrexate (day 1, 3, 6). Eighteen patients developed grade >/= II GVHD at a median time of 22 days (extreme values : 14 to 39 days), and were treated with steroids. CNA was measured before transplant, and then once weekly, for at least two months. Blood was sampled before the morning dose of of CsA when the patients received it orally. CNA was determined in mononuclear cells isolated from whole blood by quantifying by HPLC the dephosphorylation of phospho-RII peptide, a substrate of calcineurine. Results : In the 18 patients who developed acute GVHD, CNA was increased at day 21, 28 and 42, by 11±7 (p=0.15), 40±16 (p<0.02) and 38±17 (p<0.05) pmol RII/mg proteins/min, respectively. Analysis involving the ROC curve demonstrated that acute GVHD can be predicted with a sensitivity of 89% and a specificity of 54% with the use of a cutoff value of 28 pmol RII/mg proteins/min of CNA. An increase of CNA above the threshold of 28.5 pmol RII/mg proteins/min always preceded grade >/= II acute GVHD episodes that occurred after the 3rd week following transplantation. When grade >/= II acute GVHD episodes occurred before the 3rd week following transplantation, CNA was increased above this threshold of 28.5 pmol RII/mg proteins/min in 6 out of 8 patients.
Conclusions : CNA appears as a promising therapeutic index to estimate the degree of immune suppression afforded by CsA. We are now evaluating the routine use of CNA for the dose adjustment of CsA in order to reduce acute GVHD in allogeneic SCT.
P569
Increased immune transcript levels early after transplantation may indicate acute GVHD M. Jaksch, M. Remberger, J. Mattsson (Stockholm, S) Three effector pathways have been described for cytotoxic T lymphocytes: one requires perforin and granzyme B, the second Fas and its ligand (FasL) and the third pathway, secreted molecules (e.g., TNF-a, IFN-g). We utilized real-time quantitative RT-PCR as a sensitive approach to evaluate gene expression of these immune transcripts after SCT. We evaluated gene expression in 53 patients who underwent allogeneic SCT. The patients received myeloablative (n=33) and non-myeloablative (n=20) conditioning regimens. Peripheral blood samples were analysed on day 14, 21, 24, 28, and every second week up to 3 months after transplantation. Acute GVHD was diagnosed in 38 of 53 patients. Nineteen patients developed acute GVHD grade I and 19 grades II-IV acute GVHD. Increased gene expression during acute GVHD was detected for granzyme B, perforin and FasL in all patients with acute GVHD whereas TNF-a showed a more diffuse correlation. The median increase for granzyme B was 4,1x (-4,8-183) , for perforin 4,8x (1,1-255) and for FasL 5,0x (-4,62-896) . Myeloablative treated patients showed a higher increase (3x) than patients treated with non-myeloablative regimens. No correlation between the gene expression levels and grades of acute GVHD was found in this study. In 34 patients receiving steroids as GVHD treatment, decreased gene expression of granzyme B 3,8x (1,1-40), perforin 2,7x (1,1-88), TNF-a 2,1x (1,1-9,1) and FasL 3,3x (1,1-73) was observed. In 32 of these 34 patients acute GVHD resolved. In 5 of 9 patients, where the gene expression of granzyme B, perforin, and FasL increased during GVHD-treatment, a more severe acute GVHD developed.
In 30 patients up-regulation of gene expressions was not due to GVHD. The increase was caused by bacterial infections (n=2), hemolysis (n=2), pericarditis (n=1), CMV+HSV (n=16), DLI (n=1) and unknown reasons (n=8) with median day to onset of 39 (14-87) days after SCT. We also found that the period between day 14 and 21 after SCT may be of importance. Twenty-one of 27 patients with increasing gene expression levels of granzyme B, perforin, and FasL between day 14 and 21 developed acute GVHD. However, 4 of 9 patients with decreasing gene expression levels between day 14 and 21 developed acute GVHD later on. In conclusion, although not specific for acute GVHD, quantitative assessment of immune transcripts may be of value in monitoring acute GVHD and GVHD-treatment after SCT.
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Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: long-term follow-up of a randomized study T. Ruutu, L. Volin, E. Juvonen, T. Parkkali, E. Elonen, A. Nihtinen (Helsinki, FIN) In a previously published study (Blood 2000) we randomized 108 consecutive adult patients with a malignant haematological disorder undergoing allogeneic bone marrow transplantation from an HLA-identical sibling donor to receive (n=53) or not to receive (n=55) methylprednisolone (MP) as a part of GVHD prophylaxis in addition to cyclosporine A and methotrexate. MP administration was initiated on day 14 with 0.5 mg/kg, the dose was increased to 1 mg/kg on day 21 and thereafter slowly tapered and discontinued on day 110.The cumulative incidence of acute GVHD was 19% among the patients given and 56% among those not given MP, a clinically and statistically highly significant difference (p=0.0001). There was a non-significant trend toward a lower cumulative incidence of chronic GVHD and better survival in the MP+ group. There were fewer infections and the stay at hospital was shorter among the patients given MP. No difference was seen in the relapse rate. We have now carried out a long-term follow-up to find out possible late effects of the intensified GVHD prophylaxis. The follow-up time of the living patients is 6.4 -12.7 (median 10.0) years. 58 patients survived at the time of the analysis, 31 in the MP+ and 27 in the MP-group. One patient was lost for follow-up. The survival at 8 years post-transplantation was 60% among the patients given and 49% among those not given MP (p=0.24). Among low-risk patients the survivals were 73% and 64%, respectively (p=0.36). The cumulative incidence of chronic GVHD was 36% in the MP+ and 48% in the MP-group (p=0.17). At 5 years, 2/31 patients given and 9/27 not given MP prophylaxis had signs of active chronic GVHD (p=0.02). The cumulative relapse incidence was 39% in the MP+ and 34% in the MP-group (p=0.73). There were no differences in the causes of death. Two patients in the MP+ group and one in the MP-group had developed a secondary malignancy. In conclusion, the addition of corticosteroid to cyclosporine and methotrexate in GVHD prophylaxis, resulting in a marked decrease in the incidence of acute GVHD, did not cause adverse late effects. The prevalence of chronic GVHD at five years was significantly lower among the patients given prophylactic MP.
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Relationship of gene expression of HLA-C-KIR signal system and GVHD of HLA-identical PBSCT in south-Chinese population
K. Guo (Guangzhou, CHN)
Special primer-PCR, sequence analysis and three domain structure resembling methods were used to analysis gene polymorph and molecular structure of HLA-C-KIR signal system and allo-PBSCT outcome. HLA-Cw1-A3-A7 gene frequencies were 0.29, 0.27, 0.38 respectively. HLA-Cw2, -Cw4, -Cw6 gene frequencies were lower than 0.05. HLA-Cw6-A-Cw9-A-Cw10 did not found. KIR P58 gene frequencies were 2DL4 ( The three domain structures of P58 were conformed to those reported structures set up by X diffract in Swiss protein database. The structure, surface configuration and electronic potential of P58 molecular were distinctly different in those types of P58 muted at the set for recognizing HLA-C and resembling in different P58 muted at the HLA-C binding areas out side of acid 44. Relationship of HLA-C-P58 gene matched and GVHD of three pairs donor and recipient of HLA matched allo-PBSCT in different degree of GVHD were retrospectively analyzed by P58 and HLA-C gene typing, GVHD I -II was found at the HLA-C mismatched but belong to the same type of P58 binding (HLACw3,-Cw7) . There was 2DL3 matched for HLA-C binding in the recipient, but no 2DL3 in donor. GVHD III-IV was found at the HLA-C mismatched and belong to different P58 binding type( (HLA-Cw3 and HLA-Cw2) allo-PBSCT and there was 2DL2 and 2DL3, but no 2DL1 in the donor for patient HLA-Cw2. No GVHD was found in the third patient performed HLA-C matched (HLACw*0102, HLA-Cw*0102) allo-PBSCT and there was 2DL1, 2DL2 and 2DL3 in the donor for HLA-C of recipient. The result suggested that it was important that donor P58 special recognizing and binding recipient's HLA-C in allo-PBSCT and indicated that selecting the donor whose P58 binding specific to recipient's HLA-C in allo-PBSCT may reduce GVHD development in HLA-matched allo-PBSCT.
Additional abstracts to this topic
The efficiency of ursodeoxycholic acid in treatment of limited chronic graft-versus-host disease of the liver R. Idilman, M. Arat, E.A. Soydan, I. Soykan, C. Ustun, M. Topcu, S. Karayalcin, H. Akan (Ankara, TR) Limited cGVHD of the liver is characteristically associated with elevation in serum alkaline phosphatase (ALP) and liver injury tests levels which occur after day 100 of allogeneic hematopoietic cell transplantation (alloHCT). Since other cholestatic liver disorders have responded positively to ursodeoxycholic acid (UDCA) therapy, the aim of this study was to demonstrate the long-term effect of UDCA treatment in individuals with cGVHD of the liver. Between June 1997 and January 2001, a total of 160 individuals underwent alloHCT from their HLA identical siblings in our BMT Unit. Among eligible 86 peripheral blood (PB) and 44 bone marrow (BM) recipients we observed cGVHD 64 (74%) and 20 (45.5%), respectively. We investigated 13 (8.1%) alloHCT recipients (11 PB and 2 BM, M/F ratio was 8/5, the median age was 30 years, range: 15-48 years) who had been diagnosed as limited cGVHD of the liver based on previously published criteria. Serologic studies for hepatitis B surface antigen, hepatitis B core antibody IgM, hepatitis C antibody and Cytomegalo-virus (CMV) antibody IgM were all negative. Twelve were conditioned with cyclophosphamide (CY) based regimen and one received a non-myeloablative regimen. All individuals received short-term methotrexate and CsA as GVHD prophylaxis. UDCA was given orally in divided doses of 10-15 mg/kg/day for one year. After diagnosis of cGVHD, if patients were on immunosuppressive therapy, the dose of such immunosuppressive therapy was not changed, and if not, UDCA was administered alone. Drug compliance was assessed at selected intervals. The quantity of CD34+ cells transplanted ranged 2.1 X 10x6 per kilogram to 7.4x10e6 per kilogram (the mean number: 4.9 X 10e6 per BW). cGVHD of the liver was diagnosed after a median of 7 months (range:4 -42). During diagnosis, seven recipients did not take any immunsuppresive therapy while the remaining s ix recipients were on immunsuppresive therapy. A significant decrease in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (gGTP) and serum ALP levels from baseline to end of the treatment were observed (Table) (p<0.05). None of the patients was withdrawn from the study as a result of adverse effects of UDCA therapy.Based upon these results, limited cGVHD of the liver is a not rare complication of alloHCT and UDCA seems to be an effective and safe treatment modality in the long-term follow-up of chronic GVHD of the liver.
GVHD prophylaxis with thymoglobulin or atg fresenius (Atgf) in patients allografted from matched unrelated donors F. Locatelli, A. Busca, C. Boccomini, C. Ceretto, A.M. Dall'Omo, P. Affaticati, E. Gallo, M. Falda (Turin, Palermo, I) ATG is widely used before HSCT with MUD to prevent rejection and GVHD. However, optimal dosage is still under debate. Aim of the study: to compare two different doses of pre-graft rabbit ATG added to the conventional post-transplant GVHD prophylaxis with CyA and short-course MTX. Methods: between march 2000 and november 2002, 24 adult patients with hematological malignancies received HSCT from ABDRB1-matched (n=22) or mismatched (n=2) unrelated donors. The source of stem cell was BM in 19 cases, PBSC in 2 cases and umbilical cord blood in 3 cases. Patients were prospectively assigned to receive thymoglobulin (Thymo) at the dose of 10 mg/kg over 5 days pre-transplant (n=11) or ATG-F at the dose of 15 mg/kg over 5 days pre-transplant (n=13). Seven patients in the Thymo group had late disease stage, compared to 8 patients in the ATG-F group. Results: median time to reach ANC>0.5 x 10^9/l was 19 days (14-28) in the Thymo group and 20 days in the ATG-F group (p=0.2). Severe acute GVHD (grade III-IV) occurred in 3/11 (27%) patients receiving Thymo, and in 2/10 (20%) patients receiving ATG-F (p=1). Clinical chronic GVHD developed in 2 of the 4 (50%) evaluable patients in the Thymo group, and in 7 of the 8 (87%) evaluable patients in the ATG-F group (p=0.2). The incidence of CMV infection and bacteremia were respectively 72% and 60% in the Thymo group as compared to 50% and 16% in the ATG-F group. Nine patients in the Thymo group died of transplant-related complications: primary cause of death were invasive fungal infection (n=2), acute GVHD and TTP (n=2), acute GVHD and hepatic failure (n=1), MOF (n=3) and bacterial infection (n=1); three patients in the ATG-F group died of progressive disease, 4 patients died of transplant-related complications: primary cause of death were MOF (n=2), invasive fungal infection (n=1) and congestive heart failure (n=1). With a median follow-up of 705 days (30-993) the overall survival was 18% in the Thymo group and 46% in the ATG-F group (p=0.2). Conclusion: the incidence of severe acute and chronic GVHD was not significantly different between the two groups, whereas there was a higher rate of transplantrelated complications among patients receiving pre-graft Thymo. Due to the small number of patients included in the study, the results should be considered suggestive rather than definitive.
Long-term evaluation of hematopoietic and immune reconstitution following allogeneic peripheral blood hematopoietic cell transplantation during graft-versus-host disease I. Dilek, G. Gürman, K. Dalva, M. Beksac, O. Ilhan, M. Özcan, H. Akan, Ö. Arslan, N. Konuk, A. Uysal, H. Koc (Van, Ankara, TR) Objective: The reconstitution of T lymphocyte subsets following alloPBSCT was studied using flow cytometry in 22 patients with hematological malignancies. Methods: Peripheral blood hematopoietic cells were mobilized using G -CSF 10 µg/kg/day. A median of 13.7x106 CD34+ cells/kg (recipient body weight), 6.7x108 MNCs/kg, 379.3x106 total lymphocytes/kg and 267.7x106 CD3+ cells/kg were collected. Cyclosporin A and short course methotrexate were used for GVHD prophylaxis. Results: Neutrophil engraftment was significantly faster in patients with AML or chronic GVHD. Incidences of acute and chronic GVHD were 41% and 58% respectively. Chronic GVHD incidence was correlated with the number CD8+ cell in the harvest and with the count of lymphocyte in the fourth month. In patients with GVHD CD3+DR+ cells during the second month were higher compared to the GVHD (-) group, similarly CD8+ and CD3+ cells in the fourth month significantly. Remarkably, these were more prolonged in patients with chronic GVHD. CD3+DR+, CD8+ cells and total lymphocyte numbers were significantly higher in the third month with GVHD. Seven of 22 (31%) patients died after a median of 200 relapse free days. Conclusion: Based on our data we suggest that T cell subset mobilization might be helpful for understanding of the pathophysiology of GVHD and follow up of CD4+, CD8+ and activated T cells might be predictive for chronic GVHD development.
Relationship of tacrolimus blood levels to efficacy and safety outcomes after allogeneic bone marrow transplantation using a matched unrelated donor (MUD) T. Iguchi, T. Mori, R. Watanabe, Y. Aisa, T. Shimizu, Y. Tsukada, Y. Ikeda, S. Okamoto (Tokyo, JP) Tacrolimus has been proved effective for preventing acute graftversus-host disease (AGVHD) after unrelated donor marrow transplantation; however, the optimal target range of tacrolimus blood level remains unclear. The purpose of this study was to determine whether the incidence of moderate to severe AGVHD and renal dysfunction as well as hyperglycemia correlated with tacrolimus blood level. Forty nine adults received a myeloablative preparative regimen and unmanipulated bone marrow graft from an HLA-serologically matched unrelated donor. Tacrolimus was administered at 0.03mg/kg/day by continuous infusion from day -1 and the dose was adjusted to maintain whole blood steady state or trough levels between 10 and 20 ng/ml. Tacrolimus was converted to oral, and started tapering on day 50 and discontinued around day 180. Methotrexate (MTX) was given on days 1,3,6, and 11. The incidence of grade II to IV AGVHD was 55%, and that of grade III to IV was 20%. Tacrolimus blood levels were averaged in the first three weeks, and Cox models were used with averaged blood levels as time-dependent covariate. The mean blood concentration of tacrolimus during the first three weeks was identified as only the risk factor to develop moderate to severe AGVHD (p=0.024, Odds 0.67, CI 0.46-0.95), while the dosage of MTX (p=0., Odds 1.01, CI 0.91-1.16), HLA allele disparities (p=0.54, Odds 1.52, CI 0.38-6.10), and sex mismatch (p=0.15, Odds 0.30, CI 0.06-1.56) were not identified as risk factors. No significant change was observed in the risks of doubling of creatinine, or hyperglycemia (BS greater than 200 mg/dl on two consecutive days) over a tacrolimus blood level range of 10 to 20 ng/ml until two weeks after the transplant. However, tacrolimus blood level equal to or greater than 15 ng/ml was significantly associated with the occurrence of hyperglycemia in the third week of transplant (p=0.007). This analysis supports the importance of close monitoring of tacrolimus blood level and to maintain its level in the range of 15 to 20 ng/ml during the first three weeks after transplantation. Results: Oral lichenoid lesions of CGVHD were detected in a mean time of 8.5±5.63 months after AHCT. Symptoms reported by the patients were xerostomia (32%), pain (24%) and odynophagia (4%), whereas 48% of the patients were asymptomatic. White plaques in the oral mucosa (72%) were the most frequent manifestation followed by erosions-ulcers (52%), erythema (20%) and white reticular striae (16%). Buccal mucosa (64%), labial mucosa (52%), lingual mucosa (32%), gingiva (8%) and oropharynx (4%) were the involved areas. Three patients (12%) had lichenoid lesions in the oral mucosa without cutaneous signs of CGVHD. Oral lichenoid lesions were seen 1 to 3 months prior to the onset of cutaneous lesions of CGVHD in 3 patients (12%), synchronously with cutaneous lesions in 5 patients (20%) and after the occurrence of cutaneous CGVHD in 14 patients (56%). These patients showed cutaneous CGVHD in a mean period of 5.8±3.16 months after the HCT. Twenty-two out of 25 patients (88%) had additional organ involvement; liver in 81.8%, eye in 50%, lung in 27.3%, gastrointestinal system in 18.2% and kidney in 4.5% of the patients. Conclusions: Oral lichenoid lesions may present with a variety of clinical manifestations. Most of the patients with these lesions also have extensive CGVHD. T his study emphasizes that recognition of oral lichenoid lesions can improve the diagnosis and the assessment of CGVHD.
Late-onset non-infectious pulmonary complications after bone marrow transplantation from matched unrelated donor C. Skert, F. Patriarca, S. Prosdocimo, C. Fili, A. Sperotto, A. Geromin, M. Cerno, R. Fanin (Udine, I) Objectives: We evaluated incidence, clinical outcome and risk factors of late-onset non infectious pulmonary complications (LONIPCs) in patients with haematological disorders submitted to BMT from a matched unrelated donor (MUD). Methods: Thirty-nine patients surviving at least 3 months after MUD BMT were analyzed. Median age at transplantation was 32 years (range14-56). Twenty-eight per cent had a diagnosis of AML, 33% ALL, 26% CML, 5% NHL, 5% MDS; 3% MI. Sixty-two per cent had advanced disease (> 2 CR, relapse, accelerate/blastic phase of CML) at transplantation. Conditioning regimen was TBI plus cyclophosphamide in 92% of the patients and the source of stem cells was the marrow in 82%. GVHD prophylaxis was cyclosporine and methotrexate. PFTs were performed in all patients before transplant and every 3 months after BMT. Results: LONIPCs was diagnosed in 10 out 39 (26%) of the patients at a median time of 8 months (3-15) after transplantation. Four patients had bronchiolitis obliterans (BO), 4 patients had bronchiolitis obliterans with organizing pneumonia (BOOP) and the remaining 2 cases had interstitial pneumonia (IP). The diagnosis of BO was mainly based on the obstructive pattern showed by PFTs, in the other cases abnormal CT findings and transbronchial biopsy contributed to appropriate classification. Advanced disease at transplantation and chronic extensive GVHD were the only variables significantly associated with the onset of LONIPC (P= 0.01 and P=0.001 respectively). Age, previous history of smoking or pulmonary disease, previous ASCT, source of stem cells, incidence of acute GVHD or CMV infection were not significantly associated with LONIPC. Pre-BMT PFTs of patients with LONIPC were similar to controls, but forced expiratory volume in 1s to forced vital capacity ratio (FEV1/FVC) and diffusing capacity (DLCO) decreased significantly at the third month-evaluation after BMT in patients who developed LONIPCs in comparison with controls (p=0.0001 and p=0.0005 respectively) and worsened during the follow-up. Therapy was cyclosporine and prednisone in 7 cases, tacrolimus and prednisone in 3 and thalidomide in one patient. At a median follow-up of 20 months from transplantation, only 2 patients were alive with an improvement of lung function. Conclusions: We conclude that advanced disease at transplantation, chronic extensive GVHD, decreased FEV1/FVC and DLCO 3 months after BMT were risk factors for the development of LONIPCs.
Prolonged administration of anti-Interleukin-2 receptor monoclonal antibody therapy for severe steroid-refractory acute graft-versus-host disease: preliminary report of a pilot study V. Soumelis, R. Delarue, I. Hirsch, B. Benettaib, O. Hermine, C. Besson, B. Varet, A. Buzyn (Paris, F) Steroid refractory acute graft versus host disease (aGVHD) remains a major life-threatening complication of allogeneic stem cell transplantation. Anti-interleukin-2 receptor (anti-IL-2R) monoclonal antibody therapy has been used with response rates of 30-40% in this indication, but whether a prolonged administration could further improve its efficiency is not known. We initiated a pilot study of anti-IL-2R therapy for steroid refractory grade III-IV aGVHD where treatment was prolonged for at least 6 weeks in responding pts. Five pts were treated to date. Three pts with AML, CML or CLL received a conventional myeloablative conditioning regimen (high-dose cyclophosphamide and TBI) and a GVHD prophylaxis with ciclosporin and short course methotrexate. Two pts with myeloma or mantle cell lymphoma received a fludarabine-based non-myeloablative regimen, with ciclosporin and mycophenolate mofetyl as GVHD prophylaxis. Stem cell source was bone marrow in two pts and peripheral blood in three. All pts had aGVHD that was refractory to either corticosteroids 2 mg/kg/day for 5 days or 5-10 mg/kg/day for 2d. Anti-IL-2R therapy was used at 1mg/kg/d for 7d followed by 1mg/kg weekly for 6 weeks and a tapering to 1mg/kg every 2 weeks until complete response (CR) was achieved. Three CRs were observed after 4d (grade III gut aGVHD), 5 weeks (grade IV skin and gut) and 10 weeks (grade III liver and gut) respectively. In the patient in CR at day 4, the GVHD relapsed in a cutaneous resistant form 10d after the end of the 6 weeks anti-IL-2R treatment, suggesting that a longer treatment could have been usefull to maintain response. One patient with grade IV skin and lung GVHD had a partial response after 1 week of treatment but died of acute intra-alveolar hemorrage. The last patient had a grade IV skin and liver GVHD that progressively appeared after immunosuppressive therapy was drastically diminished to allow a GVL effect because of multiple myeloma progression. This GVHD did not respond to anti-IL-2R nor ATG therapy. In these five patients, anti-IL-2R was well tolerated, but an extended follow-up will be necessary to evaluate any late toxicity. These preliminary data suggest that a prolonged treatment could increase the complete response rate to anti-IL-2R, especially in gut aGVHD.
Puva Combi light Uva irradiator: a new equipment to Puva treatment in Extra Corporeal Photopheresis: in vitro assays and ex vivo clinical employment C. Tassi, P.L. Tazzari, F. Ricci, A.M. Martelli, V. Giudice, A. Nannetti, R. Conte (Bologna, I) UVA and 8 -methoxypsoralen (8-MOP) treatments of lymphomonocyte collections induce immunomodulation in cGVHD and Scleroderma patients. In three steps ECP schedule, the collected mononuclear cell fraction is incubated with 8-MOP, 2J/cm square UVA irradiated, finally reinfused to patient. UVA irradiation might be performed by an UVA radiator suitable to blood treatment. To validate the clinical use of PUVA Combi LIGHT (Dermat BVBA, Belgium) equipment, preliminary "in vitro" assays were carried out to assess the efficiency in inducing apoptosis and cell proliferation inhibition. Samples from peripheral blood of ten normal donors, six scleroderma and two cGVHD patients candidate to photopheresis were studied. Control and PUVA treated cells were cultured in PHA-RPMI medium for three days. At day+1 and +3, apoptosis and cell viability were detected by Annexin V and 7-AAD dye and proliferating cells were stained by Ki67. Mean increment of 4-5 folds in the 7-AAD+/Annexin V+ fraction was detected at day +1 in treated samples and at day+3 overall treated cells were apoptotic showing a completely inhibited proliferating ability, in comparison to control cells. Functional studies were in addition performed. In particular DC (dendritic cells) were obtained in DC cultures from PUVA treated CD14+ immunomagnetic enrichments and their ability as APC was tested in autologous and allogeneic lymphocyte mixed cultures. Finally, thirty six samples were studied from ECP procedures carried out in three scleroderma patients: the apoptosis trend and severe inhibition of cell proliferation were obtained in all "ex vivo" treatments. In conclusion, the PUVA COMBI Light equipment can be employed in ECP as results obtained were unvarying and the irradiation procedure resulted simple and fast.
Use of mars in treatment of acute graft-versus-host disease with hepatic encephalopathy S. Wilhelm, C. Kahl, H. Hickstein, J. Freytag, D. Wolff, B. Steiner, M. Leithäuser, J. Casper, M. Freund (Rostock, D) We report a case where the Molecular Adsorbents Recirculating System (MARS) was used in an acute GvHD (aGvHD) of the liver. A 54 year old male with impaired pretransplant liver function received an allogeneic peripheral blood stem cell transplantation from a HLA-ident related donor on for AML M4 with trilineage dysplasia. Conditioning regimen consisted of 12 Gy total body irradiation in six fractions with shielding of the lungs (7 Gy) (d-8 to d-6) and Ara-C 2 x 3 g/m² (d-5 to d-2). Graft versus host prophylaxis consisted of cyclosporin A (3mg/kg) and MMF (2x1g/d) (d+1 to d+28). The graft contained 2,83 x 106/kg CD34+ cells. On day +35 post PBSCT he developed acute GvHD IV° (generalized erythroderma with desquamation, severe diarrhoea and elevated serum bilirubin). Response to Methylprednisolon 2mg/kg was only temporary. Therefor at day 44 treatment with the humanized IL-2 receptor antibody DaclizumabR in combination with the TNF-receptor fusion protein EtanerceptR was initiated. Despite response of skin and gut GVHD, the liver function remained severely impaired with elevated ammonia, bilirubin, gamma-GT, alkaline phosphatase, ALT and AST. At the same time the patient developed an alteration of mental status (delirium, lethargy, brain stem signs). Due to the impaired liver function MARS therapy was initiated. In response to the MARS therapy the patient regained his consciousness; a significant neurological improvement and the treatment was associated with significant reduction of bilirubin. After the third MARS cycle a TTP like syndrom after BMT with hemolysis, fragmentocytes and elevated LDH was detected and the patient died d+150 after PBSCT on a fungal severe sepsis. We did not observe any side effects relating to MARS treatment.
